Application of traditional Chinese medicine composition in preparation of medicine for improving erythrocyte function
By regulating the levels of MDA, ROS, Na+-K+-ATPase, and 2,3-DPG in erythrocytes using a traditional Chinese medicine composition, the problem of abnormal erythrocyte function was solved, cellular oxygen transport and stability were improved, and the aging process was delayed.
Patent Information
- Application Number
- CN202311669867.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-04-06
- Filing Date
- 2023-12-06
- Publication Date
- 2024-11-19
AI Technical Summary
In the existing technology, abnormal red blood cell function is closely related to a variety of diseases, especially in cancer, hematological diseases and aging. Abnormalities in MDA, ROS, Na+-K+-ATPase activity, 2,3-DPG levels and membrane protein expression lead to cell damage and dysfunction.
A traditional Chinese medicine composition, consisting of Cuscuta chinensis, Lycium barbarum, Schisandra chinensis, Cnidium monnieri, Rosa laevigata, Allium tuberosum, Morinda officinalis, Cistanche deserticola, Rehmannia glutinosa, Achyranthes bidentata, Epimedium brevicornu, Rubus idaeus, Panax ginseng, Cervus nippon, Hippocampus, and Melia toosendan, was used to significantly reduce MDA and ROS levels, increase Na+-K+-ATPase activity and 2,3-DPG levels, regulate membrane protein expression, and improve erythrocyte function.
It significantly reduces MDA and ROS levels, increases Na+-K+-ATPase activity and 2,3-DPG levels, improves erythrocyte function, delays aging, enhances cell membrane stability and oxygen transport capacity, and reduces vesicle release from senescent erythrocytes.
Smart Images

Figure CN118976072A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of traditional Chinese medicines, and in particular relates to a new therapeutic use of a traditional Chinese medicine composition. Background Art
[0002] Red blood cells are the most numerous type of blood cells in the blood. They are also the main medium for transporting oxygen through the blood in vertebrates. The normal function of red blood cells is closely related to human health. There are many parameters that reflect the function of red blood cells, including red blood cell MDA (malondialdehyde), ROS (reactive oxygen) level, Na + -K + -ATPase activity, 2,3-DPG level and total amount of membrane protein, etc. Changes in these indicators often mean the occurrence of disease.
[0003] MDA is the final product of lipid peroxidation, which can cause cross-linking of proteins, nucleic acids, and lipids, causing biomembrane denaturation, cell mutation, aging, or death. Therefore, measuring the MDA level can reflect the degree of lipid peroxidation in the body and indirectly reflect the degree of cell damage. Most studies believe that the serum MDA level of red blood cells in cancer patients will increase. The article "Effects of Self-Controlled Exercise on Red Blood Cell Antioxidant Enzyme Activity and Plasma Malondialdehyde Content in Cancer Patients" published by Wang Yuxia et al. shows that cancer patients are in a state of oxidative stress, and their plasma MDA levels are significantly higher than those of healthy controls.
[0004] ROS is the main cause of oxidative damage to red blood cells. It is a series of products directly or indirectly produced when molecular oxygen undergoes a reduction reaction, and exists in the form of free radicals or other highly active intermediates. Red blood cells circulate in the blood, and their oxidative damage comes from ROS produced by self-oxidation of Hb in red blood cells, among which iron is an effective catalyst for free radical reactions; on the other hand, it is ROS produced and released into the blood when nucleated cells such as white blood cells in the body undergo aerobic respiration. According to the article "Regulatory Mechanism of Ferroptosis and Research Progress in Hematological Diseases" published by Zheng Suying et al., ferroptosis is a form of programmed cell death (PCD). It is a link between metabolism, redox biology and human health, and is characterized by the lethal accumulation of ROS. Ferroptosis was first discovered in tumor cells. In recent years, it has been found that ferroptosis is closely related to blood system diseases such as leukemia, lymphoma, multiple myeloma (MM), myelodysplastic syndromes (MDS) and anemia. The article "Effects of Jianpi Bushen Recipe on the Hematopoietic System of Chemically Injured Model Mice" published by Xiao Jingjing et al. shows that chemical damage will lead to increased ROS production in hematopoietic cells and their microenvironment, exceeding the clearance capacity of the antioxidant system in the body. The body cannot accurately repair DNA damage in hematopoietic progenitor cells and hematopoietic stem cells, leading to apoptosis of hematopoietic progenitor cells and hematopoietic stem cells, reduced proliferation of hematopoietic progenitor cells, reduced ability to induce hematopoietic stem cells to self-renew and directional differentiation, damage to bone marrow stromal cells, resulting in disturbance of hematopoietic stem cell niche homeostasis, and ultimately leading to bone marrow suppression and bone marrow failure.
[0005] Na + -K + -ATPase, also known as sodium pump, is a biological membrane enzyme system widely distributed in the body, which plays an important role in maintaining the normal physiological function of cells. + -K + -ATPase is a protein embedded in the lipid bilayer of the cell membrane. It has carrier and enzyme activities. It catalyzes ATP and hydrolyzes it to provide energy, driving Na + and K + It is transported in opposite directions on both sides of the cell membrane, maintaining the membrane potential inside and outside the cell membrane and regulating the osmotic pressure of the cell, providing power for the absorption of nutrients, and playing an important role in the conduction of impulses in nerve and muscle cells. + -K + -ATPase continuously converts the chemical energy stored in ATP into the maintenance of Na + , K+ The potential energy of the transmembrane gradient, more than 40% of the red blood cell production capacity is used to maintain the normal operation of the sodium pump. + -K + -ATPase Correlation Study" Based on the combination of traditional Chinese medicine theory and modern medical theory, clinical observations were conducted on three syndromes of lung distension, Yang deficiency and water overflow syndrome, phlegm-heat stagnation in the lung syndrome, and lung-kidney qi deficiency syndrome. The red blood cell membrane sodium-potassium ATPase was used as the main detection index. The red blood cell membrane sodium-potassium ATPase levels in the three different syndromes of lung distension were studied and analyzed to explore the correlation between lung distension, Yang deficiency and water overflow syndrome and Na + -K + -ATPase. The results showed that the values of erythrocyte membrane sodium-potassium ATPase in patients with the three syndromes were all low, and the higher the lung function grade, the lower the erythrocyte membrane sodium-potassium ATPase.
[0006] In red blood cells, 2,3-DPG is an intermediate product of red blood cell glycolysis metabolism, and its concentration is one of the important factors regulating the affinity of Hb to oxygen. 2,3-DPG can enhance the deformability of RBC, thereby affecting the blood's ability to supply oxygen to tissues and its transport capacity. Benesch et al. (1968) proved that 2,3-DPG and Hb in RBC are equimolar, indicating that 2,3-DPG in RBC can reduce Hb's affinity for oxygen. When blood passes through tissues, the presence of 2,3-DPG in RBC can significantly increase the release of oxygen to meet the needs of tissues. Geng Qingqing et al. published "Adaptive Changes and Research Ideas of Red Blood Cells, Erythropoietin, and 2,3-Bisphosphoglycerate in Plateau Training", which shows that changes in the concentration of 2,3-DPG in RBC can regulate the amount of oxygen obtained by tissues, thereby improving the hypoxia condition at high altitudes.
[0007] Human erythrocyte membrane proteins are biomarkers for the diagnosis of many diseases. For example, the article “Changes in the Expression of Erythrocyte Membrane Proteins in Patients with Alzheimer’s Disease” published by Ou Fei et al. shows that the expression of erythrocyte membrane proteins in patients with Alzheimer’s disease will change significantly. The article “Changes in Erythrocyte Membrane Proteins in Rats Exposed to Low-Concentration Arsenic” published by Zhang Jing et al. also shows that the content of erythrocyte membrane proteins in rats poisoned by low-concentration arsenic will be significantly reduced, and erythrocyte membrane proteins can be used as early markers for chronic arsenic poisoning.
[0008] Chinese patent CN1403145A discloses a pharmaceutical composition for treating impotence and a preparation method thereof, the pharmaceutical composition comprises 150-350 parts of Cuscuta seeds, 100-200 parts of Lycium barbarum, 30-60 parts of Schisandra chinensis, 20-50 parts of Cnidium monnieri, 20-50 parts of Rosa laevigatae, 20-50 parts of Allium officinale, 20-50 parts of Morinda officinalis, 20-50 parts of Cistanche deserticola, 30-60 parts of Radix Rehmanniae, and 20-50 parts of Cyathula officinalis, which can improve the excitability of castrated rat penis to external stimulation, shorten the penis erection latency, and improve serum testosterone level. After this patent, research on the improvement of the composition and its scope of application has been continuously carried out, and many excellent results have been achieved, and this research is still being carried out. Summary of the invention
[0009] The purpose of the present invention is to provide a new use of a Chinese medicine composition in preparing a medicine for improving red blood cell function.
[0010] In order to achieve the above objectives, the inventors provide the following technical solutions.
[0011] The invention discloses an application of a traditional Chinese medicine composition in preparing a medicine for improving red blood cell function. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 150-350 parts of dodder seed, 100-200 parts of wolfberry fruit, 30-60 parts of schisandra chinensis, 20-50 parts of cnidium monnieri, 20-50 parts of rosa laevigata fruit, 20-50 parts of allium tuberosum seed, 20-50 parts of morinda officinalis, 20-50 parts of cistanche deserticola, 30-60 parts of raw rehmannia root, 20-50 parts of cyathula officinalis, 40-100 parts of epimedium, 20-50 parts of raspberry, 15-35 parts of ginseng, 10-25 parts of pilose antler, 15-35 parts of seahorse and 15-35 parts of toosendan fruit.
[0012] The above-mentioned traditional Chinese medicine composition is preferably made of the following raw materials in parts by weight: 150 parts of Cuscuta seeds, 200 parts of Lycium barbarum, 30 parts of Schisandra chinensis, 50 parts of Cnidium monnieri, 20 parts of Rosa laevigata, 20 parts of Allium tuberosum, 50 parts of Morinda officinalis, 20 parts of Cistanche deserticola, 30 parts of Rehmannia root, 50 parts of Cyathula capitata, 40 parts of Epimedium, 50 parts of Rubus idaeus, 15 parts of Ginseng, 25 parts of Deer antler, 15 parts of Hippocampus, and 35 parts of Toosendan.
[0013] The above-mentioned traditional Chinese medicine composition can also be preferably made of the following raw materials in parts by weight: 350 parts of Cuscuta seeds, 100 parts of Lycium barbarum, 60 parts of Schisandra chinensis, 20 parts of Cnidium monnieri, 50 parts of Rosa laevigata, 50 parts of Allium tuberosum, 20 parts of Morinda officinalis, 50 parts of Cistanche deserticola, 60 parts of Rehmannia root, 20 parts of Cyathula capitata, 100 parts of Epimedium, 20 parts of Rubus idaeus, 35 parts of Ginseng, 10 parts of Pilose antler, 35 parts of Hippocampus, and 15 parts of Toosendan.
[0014] The above-mentioned traditional Chinese medicine composition can also be preferably made of the following raw materials in parts by weight: 250 parts of Cuscuta seeds, 138 parts of Lycium barbarum, 46 parts of Schisandra chinensis, 35 parts of Cnidium monnieri, 35 parts of Rosa laevigata, 35 parts of Allium tuberosum, 35 parts of Morinda officinalis, 35 parts of Cistanche deserticola, 46 parts of Rehmannia root, 35 parts of Cyathula capitata, 70 parts of Epimedium, 35 parts of Rubus idaeus, 25 parts of Ginseng, 16 parts of Pilose antler, 21 parts of Hippocampus, and 23 parts of Toosendan.
[0015] The above-mentioned traditional Chinese medicine composition can also be preferably made of the following raw materials in parts by weight: 250 parts of Cuscuta seeds, 150 parts of Lycium barbarum, 45 parts of Schisandra chinensis, 30 parts of Cnidium monnieri, 30 parts of Rosa laevigata, 30 parts of Allium tuberosum, 30 parts of Morinda officinalis, 30 parts of Cistanche deserticola, 45 parts of Rehmannia root, 30 parts of Cyathula officinalis, 70 parts of Epimedium, 30 parts of Rubus idaeus, 20 parts of Ginseng, 19 parts of Pilose antler, 20 parts of Hippocampus, and 20 parts of Toosendan.
[0016] The dosage form of the Chinese medicine composition of the present invention can be decoction, capsule, tablet, granule, powder or pill.
[0017] In order to achieve the purpose of the present invention, the Chinese medicine composition of the present invention can be prepared into any dosage form according to the general preparation method as needed, preferably decoction, capsule, tablet, granule, powder or pill. In order to realize the above dosage forms, appropriate pharmaceutical excipients can be added when preparing these dosage forms, such as: fillers, disintegrants, lubricants, suspending agents, adhesives, sweeteners, flavoring agents, preservatives, matrix, etc. Fillers include but are not limited to starch, pregelatinized starch, lactose, mannitol, chitosan, microcrystalline cellulose, sucrose or a combination thereof; disintegrants include but are not limited to starch, pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch, cross-linked polyvinyl pyrrolidone, low-substituted hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose or a combination thereof; lubricants include: magnesium stearate, sodium lauryl sulfate, talc, silicon dioxide, etc.; suspending agents include but are not limited to polyvinyl pyrrolidone, microcrystalline cellulose, sucrose, agar, hydroxypropyl methylcellulose or a combination thereof. combinations thereof; binders include but are not limited to starch slurry, polyvinyl pyrrolidone, hydroxypropyl methylcellulose or combinations thereof; sweeteners include but are not limited to saccharin sodium, aspartame, sucrose, sodium cyclamate, glycyrrhetinic acid or combinations thereof; flavoring agents include but are not limited to sweeteners and various flavors; preservatives include but are not limited to parabens, benzoic acid, sodium benzoate, sorbic acid and its salts, benzalkonium bromide, chloroethidine acetate, eucalyptus oil or combinations thereof; matrices include but are not limited to PEG6000, PEG4000, insect wax or combinations thereof.
[0018] The present invention also provides a method for preparing the capsule of the above-mentioned Chinese medicine composition, comprising the following steps:
[0019] a. Weigh Cnidium monnieri, Cuscuta chinensis, Schisandra chinensis, and Epimedium brevicornum according to the proportion, add 6-10 times the amount of 70% ethanol, reflux extraction 1-3 times, each time for 1-3 hours, filter, combine the filtrate, and recover ethanol under reduced pressure until there is no alcohol taste, to obtain an alcohol extract;
[0020] b. Combine the medicinal material residue after alcohol extraction in step a with a proportion of wolfberry, raw rehmannia, raspberry, golden cherry, allium seeds, Morinda officinalis, and toosendan fruit, add 7-12 times the amount of water and boil for 1-3 times, each time for 1-3 hours, filter, combine the filtrate, mix with the alcohol extract obtained in step a, and concentrate under reduced pressure to a relative density of 1.25-1.30 measured at 60° C. to obtain an extract;
[0021] c. Weigh ginseng, pilose antler, seahorse, Cistanche deserticola, and Cyathula officinalis in proportion, grind them into fine powder and mix them evenly with the extract obtained in step b, dry at 60-70° C., grind, sieve, and fill capsules.
[0022] The present invention provides the use of the above-mentioned Chinese medicine composition in the preparation of a drug for improving the function of red blood cells. The functions of red blood cells include red blood cell MDA, ROS, Ca 2+ Increased levels of erythrocyte Na + -K + -Decrease in ATPase activity; decrease in erythrocyte 2,3-DPG level; decrease in the total amount of erythrocyte membrane protein; decrease in the levels of erythrocyte membrane Band3 protein and CD47 protein.
[0023] The Chinese medicine composition of the present invention can significantly reduce the MDA, ROS and Ca of red blood cells. 2+ levels, and / or significantly elevated red blood cell Na + -K + -ATPase activity, and / or significantly increase the 2,3-DPG level of erythrocytes, and / or significantly increase the total amount of erythrocyte membrane proteins, and / or significantly upregulate the expression levels of erythrocyte Band3 and CD47 proteins, and / or reduce the clustering of Band3 protein, and / or significantly increase the activity of cell membrane aminophospholipid translocase, and / or reduce the level of phosphatidylserine (PS) externalization, thereby achieving improvement of erythrocyte function.
[0024] Through experimental studies, the Chinese medicine composition provided by the present invention has the following effects:
[0025] ① It has a significant improvement effect on the survival activity of H2O2-induced damaged human erythrocyte model, can significantly reduce the MDA and ROS levels of model cells, and significantly increase Na + -K + -ATPase activity, 2,3-DPG level and the total amount of membrane protein.
[0026] ②It can significantly reduce the MDA, ROS and Ca of erythrocytes in 37℃ aged model 2+ Levels, significantly increased Na + -K + -ATPase activity, significantly improving 2,3-DPG levels; it can significantly upregulate the expression levels of Band3 and CD47 proteins in 37°C aged erythrocyte membranes, reduce the clustering of Band3 proteins, significantly increase the activity of cell membrane aminophospholipid translocases, and reduce the level of phosphatidylserine (PS) externalization.
[0027] ③ After CD47 antibody blocked the CD47 molecule on the erythrocyte membrane, the Chinese medicine composition of the present invention could still significantly reduce the ROS, MDA and Ca in the 37°C aged erythrocyte model. 2+ level.
[0028] ④ After taking the Chinese medicine composition of the present invention for 3 months, the red blood cell Na in the blood can be significantly increased. + -K + -ATPase activity and 2,3-DPG levels.
[0029] ⑤ The Chinese medicine composition of the present invention can reduce the intracellular translocation of SIRPα on the macrophage membrane induced by senescent erythrocytes by delaying the senescence of erythrocytes, and increase the expression level of SIRPα on the cell membrane.
[0030] ⑥ The Chinese medicine composition of the present invention can improve the morphology of 37°C aged human erythrocytes, significantly increase the Hb, CD47 expression and AchE enzyme activity levels of aged erythrocytes, and inhibit the release of aged erythrocyte vesicles and the loss of CD47 in a time-dependent manner.
[0031] ⑦ The Chinese medicine composition of the present invention can significantly reduce the MDA, ROS, and Ca of erythrocytes in aging mice. 2+ , Ps externalization and 2,3-DPG levels, significantly inhibited the release of erythrocyte vesicles and the loss of erythrocyte CD47, and significantly promoted the erythrocyte Hb level, Na + -K + - Increased ATPase and AChE enzyme activity levels.
[0032] Figure 1 This is a graph showing the effect of BZBS on the expression level of Band3 in 37°C aged erythrocyte membranes in Example 8.
[0033] Figure 2 This is a picture (630×) of the morphology of red blood cells and the expression and distribution of Band3 after BZBS intervention on 37° C. aged red blood cells in Example 8.
[0034] Figure 3 This is a graph showing the expression level of CD47 on erythrocyte membranes aged at 37°C as a result of BZBS intervention in Example 8.
[0035] Figure 4 This is a picture of the expression of CD47 on erythrocyte membrane after BZBS intervention on 37°C aged erythrocytes in Example 8 (630×).
[0036] Figure 5 This is a graph showing the expression levels of CD47 and Band3 in young red blood cells after intervention with the supernatant culture medium of aged red blood cells in Example 10.
[0037] Figure 6 This is the expression distribution diagram of SIRPα on the cell membrane of each group of macrophages in Example 12 (630×), green FITC: indicates the expression of SIRPα; blue Hoechst: indicates the cell nucleus.
[0038] Figure 7 This is a graph showing the expression levels of cell membrane SIRPα in each group of macrophages in Example 12.
[0039] Figure 8 This is a graph showing the protein expression level of total cellular SIRPα in each group of macrophages in Example 12.
[0040] Fig. 9 These are electron microscope photos of the red blood cell morphology of each group in Example 13.
[0041] Fig.10 This is a graph showing the expression level of Ac-α-Tubulin in red blood cells of each group in Example 14.
[0042] Fig.11 This is a bar graph showing the changes in NKA activity of red blood cells in each group in Example 14.
[0043] Fig.12 Graph showing the erythrocyte tubulin expression levels of each group in Example 15.
[0044] Fig.13 NAD of each group of red blood cells in Example 15 + Horizontal histogram.
[0045] Fig.14 These are electron microscopic photographs of the NAMPT expression levels of red blood cells in each group in Example 15.
[0046] Fig.15 This is a bar graph showing the changes in SIRT2 activity of red blood cells in each group in Example 15.
[0047] Fig.16 This is a bar graph showing the changes in HDAC6 activity of red blood cells in each group in Example 15.
[0048] Fig.17This is a bar chart comparing the changes in Hb levels in 37℃ aged human red blood cells after BZBS intervention. In the figure, vs. Control: ** P<0.01; vs. Model: # P<0.05, ## P<0.01.
[0049] Fig.18 This is a bar graph comparing the changes in AChE levels in 37°C aged human erythrocytes after BZBS intervention. In the figure, vs. Control: ** P<0.01; vs. Model: ## P<0.01.
[0050] Fig.19 This is a time-effect comparison chart of the effect of BZBS on the amount of vesicle release from aging human red blood cells. In the figure, vs. Control: ** P<0.01; vs. Model: ## P<0.01.
[0051] Fig. 20 This is a comparison chart of the time-effect relationship of BZBS on the level of CD47 in aging human red blood cells. In the figure, vs. Control: ** P<0.01; vs. Model: ## P<0.01.
[0052] Fig.21 This is a time-effect comparison chart of the effect of BZBS on the level of CD47 in the exosomes of erythrocytes of aged humans. In the figure, vs. Control: ** P<0.01; vs. Model: ## P<0.01.
[0053] Fig. 22 This is a diagram showing the changes in cell morphology and CD47 expression distribution after BZBS intervention on 37°C aged human red blood cells (630×).
[0054] Fig.23 This is a bar graph comparing the changes in CD47 fluorescence intensity of aged human red blood cells treated with BZBS at 37°C. ** P<0.01; vs. Model: ## P<0.01.
[0055] Fig.24 This is a comparison chart of the changes in ROS levels in erythrocytes of aging mice treated with BZBS. In the figure, vs. Model: ##P<0.01.
[0056] Fig.25This is a comparison chart of the changes in MDA levels in erythrocytes of aging mice treated with BZBS. In the figure, vs. Model: #P<0.05, ##P<0.01.
[0057] Fig.26 This is a comparison chart of the changes in 2,3-DPG levels in red blood cells of aging mice treated with BZBS. In the figure, vs. Model: #P<0.05, ##P<0.01.
[0058] Fig. 27 BZBS intervention of erythrocyte Na in aging mice + -K + -Comparison of changes in ATPase levels. In the figure, vs. Model: ##P<0.01.
[0059] Fig.28 This is a comparison chart of the changes in CD47 levels in red blood cells of aging mice treated with BZBS. In the figure, vs.8months: * P<0.05, ** P<0.01; vs. Model: # P<0.05, ## P<0.01.
[0060] Fig.29 This is a comparison chart of the changes in the amount of EV released from red blood cells of aging mice after BZBS intervention. In the figure, vs.8months: ** P<0.01; vs. Model: # P<0.05, ## P<0.01.
[0061] Fig.30 This is a comparison chart of the changes in the level of CD47 in erythrocyte exocytic vesicles of aging mice treated with BZBS. In the figure, vs.8months: ** P<0.01; vs. Model: ## P<0.01.
[0062] Fig.31 This is a bar graph comparing the changes in CD47 levels in red blood cells of 25-month-old mice treated with BZBS. ** P<0.01; vs. Model: ## P<0.01.
[0063] Fig.32 This is a bar graph comparing the changes in Hb levels in erythrocytes of aging mice treated with BZBS. In the figure, vs. Control: **P<0.01; vs. Model: #P<0.05, ##P<0.01.
[0064] Fig.33 This is a bar graph comparing the changes in AChE levels in erythrocytes of aging mice treated with BZBS. In the figure, vs. Control: *P<0.05; vs. Model: #P<0.05.
[0065] Fig.34 This is a bar graph comparing the changes in PS externalization levels of erythrocytes in aged mice treated with BZBS. In the figure, vs. Control: **P<0.01; vs. Model: ##P<0.01.
[0066] Fig.35 BZBS intervenes in erythrocyte Ca2+ expression in aging mice 2+ Bar chart of horizontal changes. In the figure, vs. Control: **P<0.01; vs. Model: #P<0.05, ##P<0.01.
[0067] Fig.36 BZBS intervention of human red blood cell Na + -K + -Comparison of changes in ATPase activity. In the figure, vs. Before: **P<0.01.
[0068] Fig.37 This is a comparison chart of the changes in CD47 levels in human red blood cells after BZBS intervention. In the figure, vs.Before: * P<0.05.
[0069] Fig.38 This is a comparison chart of the changes in the number of vesicle release from human red blood cells after BZBS intervention. In the figure, vs.Before: ** P<0.01.
[0070] Fig.39 This is a comparison chart of the changes in CD47 levels on human red blood cell exocytic vesicles after BZBS intervention. In the figure, vs.Before: ** P<0.01.
[0071] Fig.40 This is a comparison of the changes in the Ps eversion level of 37℃ aged human erythrocytes after BZBS intervention with CD47 blockade. In the figure, vs. Control: ** P<0.01; vs. Model: # P<0.05, ## P<0.01.
[0072] Fig.41 This is a comparison of the changes in Hb levels in 37℃ aged human red blood cells after BZBS intervention with CD47 blockade. In the figure, vs. Control: * P<0.05,** P<0.01; vs. Model: # P<0.05, ## P<0.01.
[0073] Fig.42 This is a comparison of the changes in AChE levels in 37℃ aged human erythrocytes after BZBS intervention with CD47 blockade. In the figure, vs. Control: ** P<0.01; vs. Model: ## P<0.01.
[0074] Fig.43 This is a comparison chart of the changes in the number of EVs released from aged human red blood cells at 37°C after BZBS intervention with CD47 blockade. In the figure, vs. Control: ** P<0.01; vs. Model: ## P<0.01.
[0075] Fig.44 This is a bar graph comparing the changes in 2,3-DPG levels in red blood cells after BZBS intervention with vesicle promoter induction. In the figure, vs. Control: ** P<0.01; vs. Model: ## P<0.01.
[0076] Fig.45 This is a bar graph comparing the changes in red blood cell MDA levels after BZBS intervention with vesicle promoter induction. In the figure, vs. Control: ** P<0.01; vs. Model: ## P<0.01.
[0077] Fig.46 This is a bar graph comparing the changes in ROS levels in red blood cells after BZBS intervention with vesicle promoter induction. In the figure, vs. Control: ** P<0.01; vs. Model: ## P<0.01.
[0078] Fig.47 This is an electron microscope photograph (630×) showing the changes in red blood cell morphology and CD47 expression distribution after BZBS intervention with vesicle promoter induction.
[0079] Fig.48 This is a bar graph comparing the changes in the fluorescence intensity of erythrocyte CD47 after BZBS intervention with vesicle promoter induction. In the figure, vs. Control: **P<0.01.
[0080] Fig.49 Schematic diagram of the administration and sampling time for the study of the effects of BZBS on adiponectin-induced mouse erythrocyte phenotype.
[0081] Fig.50 This is a bar graph comparing the changes in 2,3-DPG levels in mouse erythrocytes after BZBS intervention with vesicle promoter induction.
[0082] In the figure, vs.Control: ** P<0.01; vs. Model: ## P<0.01.
[0083] Fig.51 This is a bar graph comparing the changes in the level of MDA in mouse erythrocytes after BZBS intervention with vesicle promoter induction. In the figure, vs. Control: ** P<0.01; vs. Model: ## P<0.01.
[0084] Fig.52 This is a bar chart comparing the changes in PS externalization levels in mouse erythrocytes after BZBS intervention with vesicle promoter induction. In the figure, vs. Control: * P<0.05; vs. Model: ## P<0.01. DETAILED DESCRIPTION
[0085] The present invention is further described in detail below with reference to specific embodiments.
[0086] Example 1 Preparation of capsules
[0087] Prescription: Cuscuta 250g, Lycium 138g, Schisandra 46g, Cnidium monnieri 35g, Rosa laevigata 35g, Allium oleifera 35g, Morinda officinalis 35g, Cistanche deserticola 35g, Rehmannia glutinosa 46g, Cyathula officinalis 35g, Epimedium 70g, Rubus 35g, Ginseng 25g, Deer antler 16g, Hippocampus 21g, Toosendan fruit 23g.
[0088] Preparation method:
[0089] a. Weigh Cnidium monnieri, Cuscuta chinensis, Schisandra chinensis, and Epimedium brevicornum according to the proportion, add 3208 ml 70% ethanol, reflux extract 3 times, 2 hours each time, filter, combine the filtrate, and recover ethanol under reduced pressure until there is no alcohol taste to obtain an alcohol extract;
[0090] b. Combine the medicinal material residue after alcohol extraction in step a with a proportion of wolfberry, raw rehmannia, raspberry, golden cherry, allium seeds, Morinda officinalis, and toosendan fruit, add 6732 ml of water and boil twice, each time for 2 hours, filter, combine the filtrate, mix with the alcohol extract obtained in step a, and concentrate under reduced pressure to a relative density of 1.28 measured at 60° C. to obtain an extract;
[0091] c. Weigh ginseng, pilose antler, seahorse, Cistanche deserticola, and Cyathula officinalis in proportion, grind into fine powder and mix evenly with the extract obtained in step b, dry at 60-70° C., grind, sieve, and fill into capsules to obtain 757 capsules.
[0092] Example 2 Preparation of tablets
[0093] Prescription: Cuscuta 250g, Lycium 150g, Schisandra 45g, Cnidium monnieri 30g, Rosa laevigata 30g, Allium oleifera 30g, Morinda officinalis 30g, Cistanche deserticola 30g, Rehmannia glutinosa 45g, Cyathula officinalis 30g, Epimedium 70g, Rubus 30g, Ginseng 20g, Deer antler 19g, Seahorse 20g, Toosendan fruit 20g.
[0094] Preparation method:
[0095] a. Weigh Cnidium monnieri, Cuscuta chinensis, Schisandra chinensis, and Epimedium brevicornum according to the proportion, add 2765 mL of 70% ethanol, reflux extract 3 times, 1 hour each time, filter, combine the filtrate, and recover ethanol under reduced pressure until there is no alcohol taste to obtain an alcohol extract;
[0096] b. Combine the medicinal material residue after alcohol extraction in step a with the prescribed amount of wolfberry, raw rehmannia, raspberry, golden cherry, allium seeds, Morinda officinalis, and toosendan fruit, add 5110 ml of water and boil once for 3 hours, filter, combine the filtrate, mix with the alcohol extract obtained in step a, and concentrate under reduced pressure to a relative density of 1.25 measured at 60° C. to obtain an extract;
[0097] c. Weigh ginseng, pilose antler, seahorse, Cistanche deserticola, and Cyathula officinalis in proportion, grind them into fine powder and mix them evenly with the extract obtained in step b, dry at 60-70° C., grind, sieve, add 1% magnesium stearate, and press into tablets to obtain tablets.
[0098] Example 3 Preparation of pills
[0099] Prescription: Cuscuta 350g, Lycium 100g, Schisandra 60g, Cnidium monnieri 20g, Rosa laevigata 50g, Allium oleifera 50g, Morinda officinalis 20g, Cistanche 50g, Rehmannia glutinosa 60g, Cyathula officinalis 20g, Epimedium 100g, Rubus 20g, Ginseng 35g, Deer antler 10g, Seahorse 35g, Toosendan fruit 15g.
[0100] Preparation method:
[0101] a. Weigh Cnidium monnieri, Cuscuta chinensis, Schisandra chinensis, and Epimedium brevicornum according to the proportion, add 5300 mL of 70% ethanol, reflux extract once for 3 hours, filter, combine the filtrate, and recover ethanol under reduced pressure until there is no alcohol taste to obtain an alcohol extract;
[0102] b. Combine the medicinal material residue after alcohol extraction in step a with the prescribed amount of wolfberry, raw rehmannia, raspberry, golden cherry, allium seeds, Morinda officinalis, and toosendan fruit, add 10140 mL of water and boil for 3 times, each time for 1 hour, filter, combine the filtrate, mix with the alcohol extract obtained in step a, and concentrate under reduced pressure to a relative density of 1.26 measured at 60° C. to obtain an extract;
[0103] c. Weigh ginseng, pilose antler, seahorse, Cistanche deserticola, and Cyathula officinalis in proportion, grind them into fine powder and mix them evenly with the extract obtained in step b, dry at 60-70° C., grind, sieve, and make pills.
[0104] Example 4 Preparation of granules
[0105] Prescription: 150g of Cuscuta seeds, 200g of Lycium barbarum, 30g of Schisandra chinensis, 50g of Cnidium monnieri, 20g of Rosa laevigata, 20g of Allium tuberosum seeds, 50g of Morinda officinalis, 20g of Cistanche deserticola, 30g of Rehmannia root, 50g of Cyathula capitata, 40g of Epimedium, 50g of Rubus idaeus, 15g of Ginseng, 25g of Deer antler, 15g of Hippocampus, and 35g of Toosendan seeds.
[0106] Preparation method:
[0107] a. Weigh Cnidium monnieri, Cuscuta chinensis, Schisandra chinensis, and Epimedium brevicornum according to the proportion, add 2430 mL of 70% ethanol, reflux extract twice, each time for 1.5 hours, filter, combine the filtrate, and recover ethanol under reduced pressure until there is no alcohol taste to obtain an alcohol extract;
[0108] b. Combine the medicinal material residue after alcohol extraction in step a with the remaining medicinal materials in the prescription amount, add 8800 mL of water and boil for 3 times, each time for 1 hour, filter, combine the filtrate, mix with the alcohol extract obtained in step a, and concentrate under reduced pressure to a relative density of 1.28 measured at 60° C. to obtain an extract;
[0109] c. Evenly mix the extract obtained in step b with 300 g of dextrin and 200 g of sucrose powder, dry at 60-70° C., crush, sieve, and granulate to obtain granules.
[0110] Example 5 Preparation of powder
[0111] Prescription: Cuscuta 250g, Lycium 150g, Schisandra 45g, Cnidium monnieri 30g, Rosa laevigata 30g, Allium oleifera 30g, Morinda officinalis 30g, Cistanche deserticola 30g, Rehmannia glutinosa 45g, Cyathula officinalis 30g, Epimedium 70g, Rubus 30g, Ginseng 20g, Deer antler 19g, Seahorse 20g, Toosendan fruit 20g.
[0112] Preparation method: Weigh the Chinese medicinal materials in proportion, mix and grind into fine powder to obtain the powder.
[0113] Example 6 Preparation of decoction
[0114] Prescription: Cuscuta 250g, Lycium 150g, Schisandra 45g, Cnidium monnieri 30g, Rosa laevigata 30g, Allium oleifera 30g, Morinda officinalis 30g, Cistanche deserticola 30g, Rehmannia glutinosa 45g, Cyathula officinalis 30g, Epimedium 70g, Rubus 30g, Ginseng 20g, Deer antler 19g, Seahorse 20g, Toosendan fruit 20g.
[0115] Preparation method: Weigh the Chinese medicinal materials in proportion, add water to cover the medicinal materials, soak for 15 minutes, heat to boil, continue to simmer for 30 minutes, filter, add water to the residue again to cover the medicinal materials, simmer again for 30 minutes, filter, combine the filtrate to obtain a decoction.
[0116] Example 7 Study on the effect of the Chinese medicine composition of the present invention on the H2O2-induced human erythrocyte damage model
[0117] 1 Experimental Materials
[0118] 1.1 Instruments and Equipment
[0119] Instrument Name Model or manufacturer Instrument Name Model or manufacturer Clean bench AIRTECH Inverted microscope Zeiss Autoclave ZEALWAY Low temperature centrifuge Eppendorf <![CDATA[CO2 Incubator]]> Thermo Form Benchtop centrifuge Corning Multifunctional ELISA reader BioTek Automated cell counter Life technologies Floor standing centrifuge Beckman Ultrasonic crusher SONICS&MATERIALS INC Digital display dry heater Labmet Flow cytometry BD
[0120] 1.2 Main Reagents
[0121]
[0122] 2 Experimental methods
[0123] 2.1 Preparation of main solution:
[0124] Preparation of β-nicotinamide mononucleotide (NMN): Weigh 3.34 mg of NMN and dissolve it in 1 mL of serum-free DMEM / F12 medium. Filter it with a 0.22 μM filter membrane to prepare a 10 mM stock solution. Store it in aliquots at -20°C and dilute it with physiological sodium chloride solution before use.
[0125] Preparation of test sample (BZBS) solution: Weigh an appropriate amount of the contents of the Chinese medicine composition capsule of the present invention prepared according to Example 1, dissolve it in DMEM / F12 medium to prepare a 50 mg / mL stock solution, filter it with a 0.22 μM filter membrane, store it in aliquots at -20°C, and dilute it with physiological sodium chloride solution before use.
[0126] 2.2 Separation of red blood cells:
[0127] Take fresh EDTA-2K anticoagulated whole blood, centrifuge at 2000rpm for 5min to remove the upper solution such as plasma, add 10 times the volume of physiological sodium chloride solution to dilute, centrifuge at 2000rpm for 5min, remove the supernatant, take the red blood cells, repeat the above steps 2 to 3 times until the supernatant is colorless, remove the supernatant, take the deposited red blood cells, add an equal volume of red blood cell preservation solution, and place at 4℃ for use.
[0128] 2.3 Experimental Grouping
[0129] Take the red blood cells and centrifuge at 2000rpm for 5 minutes, remove the upper preservation solution, add 10 times the volume of physiological sodium chloride solution and centrifuge at 2000rpm for 5 minutes to wash the cells, and then divide the cells into the following groups, with 1mL of packed red blood cells in each group:
[0130] (1) Blank group (Control): Add 1 mL of physiological sodium chloride solution and incubate at 37°C for 4 h. Centrifuge at 2000 rpm for 5 min to remove the supernatant. Wash 2-3 times and add 1 mL of physiological sodium chloride solution and continue incubating at 37°C for 1 h.
[0131] (2) Model group: Add 1 mL of physiological sodium chloride solution and culture at 37°C for 4 h. Centrifuge at 2000 rpm for 5 min to remove the supernatant. After washing 2-3 times, add 1 mL of physiological sodium chloride solution containing 80 mM H2O2 and continue to culture at 37°C for 1 h.
[0132] (3) BZBS 100 μg / mL group (100): Add 1 mL of physiological sodium chloride solution containing 200 μg / mL BZBS and culture at 37°C for 4 h. Centrifuge at 2000 rpm for 5 min to remove the supernatant. After washing 2-3 times, add 1 mL of physiological sodium chloride solution containing 80 mM H2O2 and continue to culture at 37°C for 1 h.
[0133] (4) BZBS 200 μg / mL group (200): Add 1 mL of physiological sodium chloride solution containing 400 μg / mL BZBS and culture at 37°C for 4 h. Centrifuge at 2000 rpm for 5 min to remove the supernatant. After washing 2-3 times, add 1 mL of physiological sodium chloride solution containing 80 mM H2O2 and continue to culture at 37°C for 1 h.
[0134] (5) BZBS 300 μg / mL group (300): Add 1 mL of physiological sodium chloride solution containing 600 μg / mL BZBS and incubate at 37°C for 4 h. Centrifuge at 2000 rpm for 5 min to remove the supernatant. After washing 2-3 times, add 1 mL of physiological sodium chloride solution containing 80 mM H2O2 and continue incubating at 37°C for 1 h.
[0135] (6) NMN group (NMN): 1 mL of physiological sodium chloride solution containing 100 μM NMN was added and cultured at 37°C for 4 h. The cells were centrifuged at 2000 rpm for 5 min to remove the supernatant. After washing 2-3 times, 1 mL of physiological sodium chloride solution containing 80 mM H2O2 was added and cultured at 37°C for 1 h.
[0136] 2.4 Index detection
[0137] 2.4.1 Survival activity
[0138] After the experiment, the cells were centrifuged at 2000 rpm for 5 min and the supernatant was discarded. 6 erythrocytes, add 100 μL of CellTiter- The culture medium of the detection reagent of the Reagent was equilibrated at room temperature for 10 minutes, and the luminescence value (Lum) of each group was detected by an ELISA reader. The experimental operation was strictly in accordance with the CellTiter- Reagent test instructions. The formula for calculating the cell viability of each well is as follows:
[0139]
[0140] 2.4.2 ROS Level
[0141] After the experiment, centrifuge at 2000rpm for 5 minutes to discard the supernatant, take 10μL of packed red blood cells, add 90μL of serum-free DMEM / F12 medium to resuspend, dilute DCFH-DA with serum-free DMEM / F12 medium at 1:500 to make the final concentration of the probe 10μmol / L, and incubate in a cell culture incubator at 37°C for 20 minutes. Invert and mix every 3-5 minutes to allow full contact between the probe and the cells. Wash the cells once with serum-free cell culture medium, set the excitation wavelength to 488nm and the emission wavelength to 525nm, use red blood cells without added probe as the blank control, and use flow cytometry to detect the percentage of positively labeled cells. 2.4.3 MDA and 2,3-DPG levels
[0142] After the experiment, centrifuge at 2000rpm for 5min to discard the supernatant, take 50μL of packed red blood cells, add 200μL of pre-cooled double distilled water to hemolyze, mix well, add 100μL of 95% ethanol, oscillate for 30s, add 100μL of chloroform to extract for 1min, centrifuge at 3500rpm for 8min, the liquid is divided into three layers, the upper layer is the extract, the middle layer is the hemoglobin precipitate, and the lower layer is chloroform. If the supernatant is turbid, add a small amount of solid NaCl and centrifuge at 3500rpm for 5min to clarify. After the extract is taken out, it can be directly used to determine the MDA, 2,3-DPG levels and the protein concentration of the extract.
[0143] According to the instructions of the MDA kit, add the sample and the detection reagent respectively, mix well, keep warm in a 100℃ water bath for 60 minutes (cover tightly to prevent water loss), cool in an ice bath, and centrifuge at 10000g for 10 minutes at room temperature. Pipette 150μL of the supernatant into a 96-well plate, measure the absorbance of each sample at 450nm, 532nm and 600nm, and calculate △A450=A450 respectively. 测定 -A450 空白 , △A532=A532 测定 -A532空白 , △A600=A600 测定 -A600 空白 The protein concentration (Cpr) of the extract was determined by the BCA method, and the MDA content was calculated according to the following formula:
[0144]
[0145] According to the instructions of the 2,3-DPG kit, add the sample and the detection reagent respectively. After the test, substitute the absorbance of the sample at 450nm into the standard curve to calculate the level of 2,3-DPG in the extract:
[0146]
[0147] 2.4.4 Detection of total membrane protein
[0148] After the experiment, centrifuge at 2000rpm for 5min and discard the supernatant. Take 0.5mL of packed red blood cells and wash them with physiological sodium chloride solution. Add hypotonic buffer (10mM Tris-Hcl) at a ratio of 1:10, mix well, place in a 4℃ environment for 20min, and then centrifuge at 4℃, 10000g for 10min. Carefully aspirate the dark red supernatant, add 10 times the volume of hypotonic buffer to the precipitate, mix well, and repeat centrifugation two or three times until the precipitate becomes milky white. Collect white or light pink red blood cell membranes, mix well, and use the BCA method to determine the cell membrane protein concentration (Cpr). The total membrane protein calculation formula is as follows:
[0149] Total amount of membrane protein (mg) = Cpr × V
[0150] V is the total volume of membrane proteins after extraction
[0151] 2.4.5 Na + -K + -Detection of ATPase activity
[0152] After the experiment, centrifuge at 2000rpm for 5 minutes and discard the supernatant, take about 1mL of packed red blood cells, wash once with physiological sodium chloride solution; add hypotonic buffer (10mM Tris-Hcl) at a ratio of 1:10, mix well, place in a 4℃ environment for 20 minutes, and then centrifuge at 4℃, 10000g for 10 minutes, and discard the supernatant; add 10 times the volume of hypotonic buffer to the precipitate, mix well, and repeat centrifugation two or three times until the precipitate becomes milky white, discard the supernatant and the brown fibrin-like precipitate at the bottom of the centrifuge tube, and collect the white red blood cell membrane protein.
[0153] According to Na + -K +-ATPase activity detection kit instructions Determine the absorbance of each group of membrane protein samples at 636nm, Na + -K + -ATPase activity calculation formula is as follows:
[0154]
[0155] C is the concentration of phosphorus standard solution, 0.02 μmol / mL; T is the reaction time, 10 min; V is the multiple of the total reaction volume and the sampling volume, that is, 7.8.
[0156] 3 Experimental results
[0157] 3.1 BZBS significantly increased the survival activity of H2O2-induced human erythrocyte injury model
[0158] The experimental results are shown in Table 1. Compared with the normal group, the survival activity of red blood cells in the model group was significantly reduced; compared with the model group, the survival activity of red blood cells in each BZBS group was significantly increased in a dose-dependent manner.
[0159] Table 1 Changes of survival activity of human erythrocyte model induced by H2O2 treated with BZBS
[0160]
[0161] vs.Control: ** P<0.01; vs. Model: ## P<0.01.
[0162] 3.2 BZBS significantly reduced the levels of MDA and ROS in the H2O2-induced human erythrocyte injury model
[0163] The experimental results are shown in Table 2. Compared with the normal group, the levels of MDA and ROS in erythrocytes in the model group were significantly increased; compared with the model group, the levels of MDA and ROS in erythrocytes in the medium and high doses of BZBS groups were significantly decreased.
[0164] Table 2 Changes of MDA and ROS levels in the H2O2-induced human erythrocyte injury model treated with BZBS
[0165]
[0166] vs.Control: ** P<0.01; vs. Model: ## P<0.01.
[0167] 3.3 BZBS significantly increased the Na in the H2O2-induced human erythrocyte injury model +-K + -ATPase activity
[0168] The experimental results are shown in Table 3. Compared with the normal group, the red blood cell Na + -K + -ATPase activity was significantly decreased; compared with the model group, Na + -K + -ATPase activity was significantly increased.
[0169] Table 3 BZBS intervention in H2O2-induced damage to human erythrocytes model Na + -K + -Changes in ATPase levels
[0170]
[0171] vs.Control:*P<0.05; vs.Model: ## P<0.01.
[0172] 3.4 BZBS significantly increased the 2,3-DPG level in the H2O2-induced human erythrocyte injury model
[0173] The experimental results are shown in Table 4. Compared with the normal group, the 2,3-DPG level in red blood cells of the model group was significantly decreased; compared with the model group, the 2,3-DPG level in each dose group of BZBS was significantly increased, and there was no increasing trend in the NMN group.
[0174] Table 4 Changes of 2,3-DPG levels in the H2O2-induced human erythrocyte injury model treated with BZBS
[0175]
[0176] vs.Control:**P<0.01; vs.Mode:, # P<0.05, ## P<0.01.
[0177] 3.5 BZBS significantly increases the total amount of cell membrane proteins in the H2O2-induced human erythrocyte injury model
[0178] The experimental results are shown in Table 5. Compared with the normal group, the total amount of erythrocyte membrane protein in the model group was significantly reduced; the total amount of membrane protein in each dose group of BZBS was significantly increased, which was equivalent to NMN.
[0179] Table 5 Changes of total amount of membrane protein in the model of H2O2-induced damage of human erythrocytes treated with BZBS
[0180]
[0181] vs.Control:**P<0.01; vs.Model: ## P<0.0
[0182] Example 8 Study on the effect of the Chinese medicine composition of the present invention on the 37°C aged human red blood cell model
[0183] 1 Experimental Materials
[0184] 1.1 Instruments and Equipment
[0185] Instrument Name Model or manufacturer Instrument Name Model or manufacturer Clean bench AIRTECH Inverted microscope Zeiss Autoclave ZEALWAY Low temperature centrifuge Eppendorf <![CDATA[CO2 Incubator]]> Thermo Form Benchtop centrifuge Corning Multifunctional ELISA reader BioTek Automated cell counter Life technologies Floor standing centrifuge Beckman Ultrasonic crusher SONICS&MATERIALS INC Digital display dry heater Labmet Flow cytometry BD Electrophoresis Apparatus GE Transfer membrane Biorad Dual-color infrared laser imaging system Odssey Laser confocal microscopy Zeiss Vortex mixer IKA —— ——
[0186] 2.1.2 Main reagents
[0187]
[0188] 2 Experimental methods
[0189] 2.1 Preparation of main solution:
[0190] (1) Preparation of β-nicotinamide mononucleotide (NMN): Weigh 3.34 mg of NMN and dissolve it in 1 mL of serum-free DMEM / F12 medium. Filter with a 0.22 μM filter membrane to prepare a 10 mM stock solution. Store in aliquots at -20°C and dilute with physiological sodium chloride solution before use.
[0191] (2) Preparation of test sample (BZBS) solution: Weigh an appropriate amount of the contents of the Chinese medicine composition capsule of the present invention prepared according to Example 1, dissolve it in DMEM / F12 medium to prepare a 50 mg / mL stock solution, filter it with a 0.22 μM filter membrane, store it in aliquots at -20°C, and dilute it with physiological sodium chloride solution before use.
[0192] (3) Red blood cell fixative: Take 10 μL of 50% glutaraldehyde and dilute it to 10 mL with PBS to obtain the red blood cell fixative.
[0193] (4) Red blood cell permeabilization solution: Take 1 mL of Triton-X100 and dilute it to 50 mL with PBS to obtain a 2% Triton-X100 stock solution. Take 10 μL of the stock solution and dilute it to 200 μL with PBS to obtain the red blood cell permeabilization solution.
[0194] (5) Immunofluorescence blocking solution: Weigh 2.5 g BSA and dissolve it in 50 mL PBS to prepare 5% BSA. Take 9 mL 5% BSA and add 1 mL blocking sheep serum to prepare the blocking solution for immunofluorescence.
[0195] (6) Immunofluorescence blocking solution: Take 2 mL of 5% BSA and 0.33 mL of blocking sheep serum, and dilute to 10 mL with PBS to prepare immunofluorescence blocking solution.
[0196] 2.2 Isolation of red blood cells
[0197] Take fresh EDTA-2K anticoagulated whole blood, centrifuge at 2000rpm for 5min to remove the upper solution such as plasma, add 10 times the volume of physiological sodium chloride solution to dilute, centrifuge at 2000rpm for 5min, remove the supernatant, take the red blood cells, repeat the above steps 2 to 3 times until the supernatant is colorless, remove the supernatant, take the deposited red blood cells, add an equal volume of red blood cell preservation solution, and place at 4℃ for use.
[0198] 2.3 Experimental Grouping
[0199] Take the red blood cells and centrifuge at 2000rpm for 5 minutes, remove the upper preservation solution, add 10 times the volume of physiological sodium chloride solution and centrifuge at 2000rpm for 5 minutes to wash the cells, and then divide the cells into the following groups, with 1mL of packed red blood cells in each group:
[0200] (1) Blank group (Control): Add 1 mL of physiological sodium chloride solution and culture at 4°C for 48 h.
[0201] (2) Model group: Add 1 mL of physiological sodium chloride solution and culture at 37°C for 48 h.
[0202] (3) BZBS 100 μg / mL group (100): Add 1 mL of physiological sodium chloride solution containing 200 μg / mL BZBS and culture at 37°C for 48 h.
[0203] (4) BZBS 200 μg / mL group (200): Add 1 mL of physiological sodium chloride solution containing 400 μg / mL BZBS and culture at 37°C for 48 h.
[0204] (5) BZBS 300 μg / mL group (300): Add 1 mL of physiological sodium chloride solution containing 600 μg / mL BZBS and culture at 37°C for 48 h.
[0205] (6) NMN group (NMN): 1 mL of physiological sodium chloride solution containing 100 μM NMN was added and cultured at 37°C for 48 h.
[0206] 2.4 Index detection
[0207] 2.4.1 ROS Level
[0208] After the experiment, centrifuge at 2000rpm for 5min and discard the supernatant. Take 10μL of packed red blood cells, add 90μL of serum-free DMEM / F12 medium to resuspend, dilute DCFH-DA with serum-free DMEM / F12 medium at 1:500 to a final concentration of 10μmol / L, and incubate in a cell culture incubator at 37℃ for 20 minutes. Invert and mix every 3-5 minutes to allow the probe and cells to fully contact. Wash the cells once with serum-free cell culture medium, set the excitation wavelength to 488nm, the emission wavelength to 525nm, use red blood cells without probe added as blank control, and use flow cytometry to detect the percentage of positively labeled cells.
[0209] 2.4.2 MDA and 2,3-DPG levels
[0210] After the experiment, centrifuge at 2000rpm for 5min to discard the supernatant, take 50μL of packed red blood cells, add 200μL of pre-cooled double distilled water to hemolyze, mix well, add 100μL of 95% ethanol, oscillate for 30s, add 100μL of chloroform to extract for 1min, centrifuge at 3500rpm for 8min, the liquid is divided into three layers, the upper layer is the extract, the middle layer is the hemoglobin precipitate, and the lower layer is chloroform. If the supernatant is turbid, add a small amount of solid NaCl and centrifuge at 3500rpm for 5min to clarify. After the extract is taken out, it can be directly used to determine the MDA, 2,3-DPG levels and the protein concentration of the extract.
[0211] According to the instructions of the MDA kit, add the sample and the detection reagent respectively, mix well, keep warm in a 100℃ water bath for 60 minutes (cover tightly to prevent water loss), cool in an ice bath, and centrifuge at 10000g for 10 minutes at room temperature. Pipette 150μL of the supernatant into a 96-well plate, measure the absorbance of each sample at 450nm, 532nm and 600nm, and calculate △A450=A450 respectively. 测定 -A450 空白 , △A532=A532 测定 -A532 空白 , △A600=A600 测定 -A600 空白 The protein concentration (Cpr) of the extract was determined by the BCA method, and the MDA content was calculated according to the following formula:
[0212]
[0213] According to the instructions of the 2,3-DPG kit, add the sample and the detection reagent respectively. After the test, substitute the absorbance of the sample at 450nm into the standard curve to calculate the level of 2,3-DPG in the extract:
[0214]
[0215] 2.4.3Na + -K + -ATPase activity
[0216] After the experiment, centrifuge at 2000rpm for 5 minutes, take out about 1mL of packed red blood cells, wash once with physiological sodium chloride solution; add hypotonic buffer (10mM Tris-Hcl) at a ratio of 1:10, mix well, place in a 4℃ environment for 20min, and then centrifuge at 4℃, 10000g for 10min, discard the supernatant; add 10 times the volume of hypotonic buffer to the precipitate, mix well, and repeat centrifugation two or three times until the precipitate becomes milky white, discard the supernatant and the brown fibrin-like precipitate at the bottom of the centrifuge tube, and collect the white red blood cell membrane protein.
[0217] According to Na + -K + -ATPase activity detection kit instructions Determine the absorbance of each group of membrane protein samples at 636nm, Na + -K + -ATPase activity calculation formula is as follows:
[0218]
[0219] C is the concentration of phosphorus standard solution, 0.02 μmol / mL; T is the reaction time, 10 min; V is the multiple of the total reaction volume and the sampling volume, that is, 7.8.
[0220] 2.4.4Ca 2+ level
[0221] After the experiment, centrifuge at 2000rpm for 5min and discard the supernatant. Take 10μL of packed red blood cells, add 90μL of PBS to resuspend, dilute Fluo-4 fluorescent probe with PBS at 1:500 to a final concentration of 2μM, and incubate in a cell culture incubator at 37℃ for 30min. Invert and mix every 3 to 5 minutes to allow the probe and cells to fully contact. Wash the cells twice with PBS, set the excitation wavelength to 488nm and the emission wavelength to 525nm, use red blood cells without probe added as blank control, and use flow cytometry to detect the percentage of positively labeled cells.
[0222] 2.4.5 Expression levels of Band3 and CD47 (Western Blot)
[0223] After the experiment, the erythrocyte membrane protein was separated according to the experimental method in 1.2.4.4, centrifuged at 18000rpm for 20min, the supernatant was removed, 100μL 2% SDS (containing 10μM PMSF) was added to lyse the membrane protein, centrifuged at room temperature (12000×g, 30min), the supernatant was taken, and the protein content in the supernatant was determined using the BCA protein detection kit. After adjusting the protein concentration, 5× Loading Buffer was added, heated at 70℃ for 10min, and the electrophoresis sample was prepared. Take an equal amount of protein sample and perform SDS-polyacrylamide gel electrophoresis (SDS-PAGE) in a 4-20% gel, transfer the protein to a nitrocellulose membrane (NC), block with blocking solution at 37℃, incubate with Band3, CD47, Actin primary antibodies (1:1000), wash with TBST, incubate with fluorescent secondary antibodies (1:5000 dilution), wash with TBST, and scan with the Odyssey protein imaging system.
[0224] 2.4.6 Expression level of CD47 (flow cytometry)
[0225] After the experiment, centrifuge at 2000rpm for 5 minutes, take about 10μL of packed red blood cells into a flow tube, wash twice with PBS, add 90μL 1% BSA and 5μL Fc segment blocking antibody, and incubate at room temperature for 5-10 minutes. Add 4μL CD47 antibody and incubate at 4℃ for 20 minutes. Centrifuge at 2000rpm for 5 minutes and discard the supernatant. Add 500μL PBS to each tube and wash twice. Finally, resuspend with 500μL PBS, set the excitation wavelength to 488nm and the emission wavelength to 525nm. Red blood cells without CD47 antibody were used as blank controls, and the expression level of CD47 on the red blood cell membrane of each group was detected by flow cytometry.
[0226] 2.4.7Band3 and CD47 immunofluorescence imaging
[0227] After the experiment, centrifuge at 2000rpm for 5min to discard the supernatant, take 10μL of packed red blood cells and place them in a 1.5mL centrifuge tube, wash three times with PBS, add 100μL of fixative and fix at room temperature for 10min, wash three times with PBS, permeabilize with 100μL of permeabilization solution for 5min, wash three times with PBS, add 100μL of blocking solution and block at 37℃ for 1h, dilute Band3 and CD47 antibodies (1:200) with conditional blocking solution, add 100μL of antibody to each and incubate overnight, wash three times with PBS, dilute secondary antibody (1:200) with conditional blocking solution, add 100μL of antibody to each and incubate for 1h, wash three times with PBS, take an appropriate amount of red blood cells, add mounting medium and coverslip, and image with laser confocal microscope.
[0228] 2.4.8 Phosphatidylserine (PS) externalization level
[0229] After the experiment, centrifuge at 2000rpm for 5 minutes, take about 10μL of packed red blood cells into a flow tube, wash twice with pre-cooled PBS, add 500μL 1×Binding Buffer to resuspend the cells, add 5μL Annexin V-FITC to each tube, gently vortex to mix, and incubate at room temperature in the dark for 5 minutes. Set the excitation wavelength to 488nm and the emission wavelength to 525nm, and use flow cytometry to detect the PS eversion level of each group of cells.
[0230] 2.4.9 Aminophospholipid translocase activity
[0231] After the experiment, centrifuge at 2000rpm for 5 minutes, take about 1μL of packed red blood cells and incubate in PBS buffer containing 0.25% BSA and 1μmol / L NBD-PS for 30 minutes. After incubation, the red blood cell sample was immediately placed on ice and divided into two parts. One sample was centrifuged at 1500rpm for 5 minutes at 4°C, the precipitate was resuspended in 200μL PBS buffer containing 1% BSA, and incubated on ice for 15 minutes; the second sample was kept on ice. After the incubation of the first sample was completed, all samples were centrifuged at 1500rpm for 5 minutes and resuspended in PBS buffer without BSA. The excitation wavelength was set to 488nm and the emission wavelength was set to 525nm, and the fluorescence level of each group of cells was detected by flow cytometry.
[0232] 3 Experimental results
[0233] 3.1BZBS significantly reduced the levels of MDA and ROS in the 37℃ aged erythrocyte model
[0234] The experimental results are shown in Table 6. Compared with the normal group, the levels of MDA and ROS in red blood cells of the model group were significantly increased; the levels of MDA and ROS in cells of each dose group of BZBS were significantly decreased.
[0235] Table 6 Changes of MDA and ROS levels in the 37℃ aged erythrocyte model treated with BZBS
[0236]
[0237] vs.Control:**P<0.01; vs.Model: # P<0.05, ## P<0.01.
[0238] 3.2BZBS significantly increased the Na of 37℃ aged erythrocyte model + -K + -ATPase activity
[0239] The experimental results are shown in Table 7. Compared with the normal group, the red blood cell Na +-K + -ATPase activity level was significantly reduced; compared with the model group, the cell Na + -K + -ATPase activity level was significantly increased.
[0240] Table 7 BZBS intervention on 37℃ aged red blood cell model Na + -K + -Changes in ATPase activity
[0241]
[0242] vs.Control:*P<0.05; vs.Model: # P<0.05, ## P<0.01.
[0243] 3.3BZBS significantly improved the 2,3-DPG level in the 37℃ aged erythrocyte model
[0244] The experimental results are shown in Table 8. Compared with the normal group, the 2,3-DPG level of red blood cells in the 37°C natural aging model group was significantly increased; compared with the model group, the 2,3-DPG level of each dose group of BZBS was significantly reduced.
[0245] Table 8 Changes in 2,3-DPG levels in the 37℃ aged red blood cell model treated with BZBS
[0246]
[0247]
[0248] vs.Control:**P<0.01; vs.Model: # P<0.05, ## P<0.01.
[0249] 3.4BZBS significantly reduced intracellular Ca in 37℃ aged cell model 2+ level
[0250] The experimental results are shown in Table 9. Compared with the normal group, the Ca 2+ Compared with the model group, the levels of Ca 2+ Levels significantly decreased.
[0251] Table 9 BZBS intervention on Ca in 37℃ aged red blood cell model 2+ Level changes
[0252]
[0253] vs.Control: ** P<0.01; vs. Model: ## P<0.01.
[0254] 3.5BZBS significantly upregulated the expression level of cell membrane Band3 protein in the 37℃ aged erythrocyte model and reduced the clustering of Band3
[0255] The results of Western Blot experiments are shown in the attached Figure 1 As shown in Table 10, compared with the normal group, the expression level of Band3 on the erythrocyte membrane in the 37°C natural aging model group was significantly decreased; compared with the model group, the expression level of Band3 in the BZBS 200 μg / mL dosage group was significantly increased.
[0256] Table 10 Changes in the expression level of Band3 in erythrocyte membranes aged at 37℃ after BZBS intervention
[0257]
[0258] vs.Control: ** P<0.01; vs. Model: # P<0.05.
[0259] The results of immunofluorescence experiments are shown in the attached Figure 2 As shown, compared with the normal group, the red blood cells in the model group were shrunken, and the Band3 protein showed obvious clustering on the red blood cell membrane; the red blood cell body in the BZBS group was plump, the membrane Band3 protein was significantly highly expressed, and was evenly distributed without clustering, and the effect was better than NMN.
[0260] 3.6BZBS significantly reduced the externalization of phosphatidylserine (PS) in the cell membrane of 37℃ aged erythrocyte model
[0261] The experimental results are shown in Table 11. Compared with the normal group, the PS eversion level of erythrocytes in the 37°C natural aging model group was significantly increased; compared with the model group, the PS eversion level of each dose group of BZBS was significantly reduced.
[0262] Table 11 Changes in PS eversion levels of 37℃ aged erythrocytes treated with BZBS
[0263]
[0264] vs.Control: ** P<0.01; vs. Model: ##P<0.01.
[0265] 3.7BZBS significantly increases the activity of aminophospholipid translocase in 37℃ aged erythrocyte model
[0266] The experimental results are shown in Table 12. Compared with the normal group, the aminophospholipid translocase activity of erythrocytes in the 37°C natural aging model group was significantly reduced; compared with the model group, the aminophospholipid translocase activity of the BZBS medium and high dose groups was significantly increased.
[0267] Table 12 Changes in aminophospholipid translocase activity of erythrocytes aged at 37℃ treated with BZBS
[0268]
[0269] vs.Control: ** P<0.01; vs. Model: ## P<0.01.
[0270] 3.8BZBS significantly increased the expression level of CD47 molecules in the 37℃ aged erythrocyte model
[0271] The results of Western Blot experiments are shown in the attached Figure 3 As shown in Table 13, compared with the normal group, the expression level of CD47 on the erythrocyte membrane in the 37°C natural aging model group was significantly decreased; compared with the model group, the expression level of CD47 in the BZBS 100 μg / mL dose group was significantly increased.
[0272] Table 13 Changes in CD47 expression levels of erythrocyte membranes aged at 37°C treated with BZBS
[0273]
[0274] vs.Control: * P<0.05; vs. Model: # P<0.05.
[0275] The results of the flow cytometry experiment are shown in Table 14. Compared with the normal group, the expression level of CD47 on the erythrocyte membrane in the 37°C natural aging model group was significantly reduced; compared with the model group, the expression level of CD47 in each dose group of BZBS was significantly increased.
[0276] Table 14 Changes in CD47 expression levels of erythrocyte membranes aged at 37℃ treated with BZBS
[0277]
[0278] vs.Control,** P<0.01; vs. Model, # P<0.05, ## P<0.01.
[0279] The results of immunofluorescence experiments are shown in the attached Figure 4 As shown in the figure, compared with the normal group, the expression of CD47 protein in the model group was significantly reduced; compared with the model group, the expression level of CD47 protein in the erythrocyte membrane of the BZBS group was significantly increased and evenly distributed.
[0280] Example 9 Study on the effect of the Chinese medicine composition of the present invention on red blood cells after CD47 antibody blocking
[0281] 1 Experimental Materials
[0282] 1.1 Instruments and Equipment
[0283] Instrument Name Model or manufacturer Instrument Name Model or manufacturer Biological Safety Cabinets AIRTECH Vortex mixer IKA Autoclave ZEALWAY Benchtop centrifuge Flying Pigeon Flow cytometry BD Multifunctional ELISA reader BioTek Constant temperature water bath Beijing Chemo Biotechnology Co., Ltd. Digital display dry heating system Labnet
[0284] 1.2 Main Reagents
[0285]
[0286] 2 Experimental methods
[0287] 2.1 Preparation of main solutions
[0288] Preparation of test sample (BZBS) solution: Weigh an appropriate amount of the powder of the contents of the capsule of the Chinese medicine composition of the present invention prepared according to Example 1, dissolve it in DMEM / F12 medium to prepare a 50 mg / mL stock solution, filter it with a 0.22 μM filter membrane, store it in aliquots at -20°C, and dilute it with physiological sodium chloride solution before use.
[0289] 2.2 Isolation of red blood cells
[0290] Take fresh EDTA-2K anticoagulated whole blood, centrifuge at 2000rpm for 5min to remove the upper solution such as plasma, add 10 times the volume of physiological sodium chloride solution to dilute, centrifuge at 2000rpm for 5min, remove the supernatant, take the red blood cells, repeat the above steps 2-3 times until the supernatant is colorless, remove the supernatant, take the deposited red blood cells, add an equal volume of red blood cell preservation solution, and place at 4℃ for use.
[0291] 2.3 IgG / CD47 antibody blocking
[0292] Take 1 mL of the above-mentioned cleaned packed red blood cells, add 1 mL of PBS (containing 1% BSA) containing 100 μg / mL CD47 or IgG antibody, incubate at 37°C for 1-2 h, centrifuge at 2000 rpm for 5 minutes, remove the supernatant, resuspend with 10 times the volume of physiological sodium chloride solution, centrifuge at 2000 rpm for 5 minutes, remove the supernatant, repeat washing 3 times, and perform subsequent drug intervention and other treatments.
[0293] 2.4 Experimental Grouping
[0294] (1) IgG blocking control group (IgG Control): After IgG antibody blocking, the red blood cells were added with an equal volume of physiological sodium chloride solution and placed at 4°C for 48 h;
[0295] (2) IgG blocking model group (IgG Model): After IgG antibody blocking, the red blood cells were added with an equal volume of physiological sodium chloride solution and placed at 37°C for 48 h;
[0296] (3) IgG blocking BZBS 100 μg / mL group (IgG 100 μg / mL): After IgG antibody blocking, the red blood cells were added with an equal volume of physiological sodium chloride solution containing 200 μg / mL BZBS and placed at 37°C for 48 h;
[0297] (4) IgG blocking BZBS 200 μg / mL group (IgG 200 μg / mL): After IgG antibody blocking, the red blood cells were added with an equal volume of physiological sodium chloride solution containing 400 μg / mL BZBS and placed at 37°C for 48 h;
[0298] (5) CD47 blocking control group (CD47 Control): Red blood cells blocked with CD47 antibody were added with an equal volume of physiological sodium chloride solution and placed at 4°C for 48 h;
[0299] (6) CD47 blocking model group (CD47 Model): Red blood cells blocked with CD47 antibody were added with an equal volume of physiological sodium chloride solution and placed at 37°C for 48 h;
[0300] (7) CD47 blocking BZBS 100 μg / mL group (CD47 100 μg / mL): Red blood cells blocked with CD47 antibody were added with an equal volume of physiological sodium chloride solution containing 200 μg / mL BZBS and placed at 37°C for 48 h;
[0301] (8) CD47 blocking BZBS 200 μg / mL group (CD47 200 μg / mL): Red blood cells blocked with CD47 antibody were added with an equal volume of physiological sodium chloride solution containing 400 μg / mL BZBS and placed at 37°C for 48 h;
[0302] 2.5 Index detection
[0303] 2.5.1Na + -K + -ATPase assay
[0304] After the experiment, centrifuge at 2000rpm for 5 minutes and discard the supernatant, take about 1mL of packed red blood cells, wash once with physiological sodium chloride solution; add hypotonic buffer (10mM Tris-Hcl) at a ratio of 1:10, mix well, place in a 4℃ environment for 20min, and then centrifuge at 4℃, 10000g for 10min, and discard the supernatant; add 10 times the volume of hypotonic buffer to the precipitate, mix well, and repeat centrifugation two or three times until the precipitate becomes milky white, discard the supernatant and the brown fibrin-like precipitate at the bottom of the centrifuge tube, and collect the white red blood cell membrane protein.
[0305] According to Na + -K + -ATPase activity detection kit instructions Determine the absorbance of each group of membrane protein samples at 636nm, Na + K + -ATPase activity calculation formula is as follows:
[0306]
[0307] C is the concentration of phosphorus standard solution, 0.02 μmol / mL; T is the reaction time, 10 min; V is the multiple of the total reaction volume and the sampling volume, that is, 7.8.
[0308] 2.5.2 Determination of MDA and 2,3-DPG
[0309] After the experiment, centrifuge at 2000rpm for 5min to discard the supernatant, take 50μL of packed red blood cells, add 200μL of pre-cooled double distilled water to hemolyze, mix well, add 100μL of 95% ethanol, oscillate for 30s, add 100μL of chloroform to extract for 1min, centrifuge at 3500rpm for 8min, the liquid is divided into three layers, the upper layer is the extract, the middle layer is the hemoglobin precipitate, and the lower layer is chloroform. If the supernatant is turbid, add a small amount of solid NaCl and centrifuge at 3500rpm for 5min to clarify. After the extract is taken out, it can be directly used to determine the MDA, 2,3-DPG levels and the protein concentration of the extract.
[0310] According to the instructions of the MDA kit, add the sample and the detection reagent respectively, mix well, keep warm in a 100℃ water bath for 60 minutes (cover tightly to prevent water loss), cool in an ice bath, and centrifuge at 10000g for 10 minutes at room temperature. Pipette 150μL of the supernatant into a 96-well plate, measure the absorbance of each sample at 450nm, 532nm and 600nm, and calculate △A450=A450 respectively. 测定 -A450 空白 , △A532=A532 测定 -A532 空白 , △A600=A600 测定 -A600 空白 The protein concentration (Cpr) of the extract was determined by the BCA method, and the MDA content was calculated according to the following formula:
[0311]
[0312] According to the instructions of the 2,3-DPG kit, add the sample and the detection reagent respectively. After the test, substitute the absorbance of the sample at 450nm into the standard curve to calculate the level of 2,3-DPG in the extract:
[0313]
[0314] 2.5.3 ROS determination
[0315] After the experiment, centrifuge at 2000rpm for 5min and discard the supernatant. Take 10μL of packed red blood cells, add 90μL of serum-free DMEM / F12 medium to resuspend, dilute DCFH-DA with serum-free DMEM / F12 medium at 1:500 to a final concentration of 10μmol / L, and incubate in a cell culture incubator at 37℃ for 20min. Invert and mix every 3-5 minutes to allow the probe and cells to fully contact. Wash the cells once with serum-free cell culture medium, set the excitation wavelength to 488nm, the emission wavelength to 525nm, use red blood cells without probe added as blank control, and use flow cytometry to detect the percentage of positively labeled cells.
[0316] 2.5.4 Ca 2+ Level determination
[0317] After the experiment, centrifuge at 2000rpm for 5min to discard the culture supernatant, take 10μL of packed red blood cells, add 90μL PBS to resuspend, dilute Fluo-4 with PBS at 1:500 to a final concentration of 2μM, and incubate in a cell culture incubator at 37℃ for 30 minutes. Invert and mix every 3 to 5 minutes to allow the probe and cells to fully contact. Wash the cells twice with PBS, set the excitation wavelength to 488nm and the emission wavelength to 525nm, use red blood cells without probe added as blank control, and use flow cytometry to detect the percentage of positively labeled cells.
[0318] 3 Experimental results
[0319] 3.1BZBS on Na of erythrocyte membrane aged at 37℃ after blocking with CD47 antibody + -K + -Effects of ATPase activity
[0320] The experimental results are shown in Table 15. Compared with the IgG blocking control group, the Na + -K + -ATPase activity was significantly decreased, and compared with the IgG blocking model group, the Na of red blood cells in the IgG blocking BZBS 100μg / mL and 200μg / mL groups was + -K + -ATPase activity was significantly increased; compared with the CD47 blocked control group, the Na + -K + -ATPase activity was significantly decreased, and compared with the CD47 blocked model group, the Na of erythrocytes in the CD47 blocked BZBS 100μg / mL and 200μg / mL groups was + -K + -ATPase activity showed no significant changes.
[0321] Table 15 BZBS intervention on 37℃ aged erythrocyte membrane Na after CD47 blocking + -K + -Changes in ATPase activity
[0322]
[0323] vs.Control:**P<0.01; vs.Model:#P<0.05,##P<0.01.
[0324] 3.2 Effect of BZBS on 2,3-DPG in 37℃ Aged Erythrocyte Model after CD47 Antibody Blocking
[0325] The experimental results are shown in Table 16. Compared with the IgG blocking control group, the 2,3-DPG level of red blood cells in the IgG blocking model group was significantly increased. Compared with the IgG blocking model group, the 2,3-DPG level of red blood cells in the IgG blocking BZBS 100 μg / mL and 200 μg / mL groups was not significantly decreased; compared with the CD47 blocking control group, the 2,3-DPG level of red blood cells in the CD47 blocking model group was significantly increased. Compared with the CD47 blocking model group, the 2,3-DPG level of red blood cells in the CD47 blocking BZBS 100 μg / mL and 200 μg / mL groups was not significantly decreased.
[0326] Table 16 Changes in 2,3-DPG levels in aged erythrocytes at 37°C after BZBS intervention with CD47 blockade
[0327]
[0328] vs.Control: ** P<0.01.
[0329] 3.3 Ca2+ in the 37℃ aged erythrocyte model after BZBS blocking CD47 antibody 2+ The impact of level
[0330] The experimental results are shown in Table 17. Compared with the IgG blocking control group, the Ca 2+ Compared with the IgG blocking model group, the Ca level of red blood cells in the IgG blocking BZBS 100μg / mL and 200μg / mL groups was significantly increased. 2+ Compared with the CD47 blocked control group, the Ca 2+ Compared with the CD47 blockade model group, the Ca level of erythrocytes in the CD47 blockade BZBS 100 μg / mL and 200 μg / mL groups was significantly increased. 2+ Levels decreased significantly.
[0331] Table 17 Ca of 37℃ aged erythrocytes after BZBS intervention on CD47 blockade 2+ Level changes
[0332]
[0333] vs.Control: ** P<0.01; vs. Model: ## P<0.01; vs.CD47 blocking Model: △△ P<0.01.
[0334] 3.4 Effect of BZBS on ROS in 37°C Aged Red Blood Cell Model after CD47 Antibody Blocking
[0335] The experimental results are shown in Table 18. Compared with the IgG blocking control group, the ROS level of red blood cells in the IgG blocking model group was significantly increased, and compared with the IgG blocking model group, the ROS levels of red blood cells in the IgG blocking BZBS100μg / mL and 200μg / mL groups were significantly decreased; compared with the CD47 blocking control group, the ROS level of red blood cells in the CD47 blocking model group was significantly increased, and compared with the CD47 blocking model group, the ROS levels of red blood cells in the CD47 blocking BZBS100μg / mL and 200μg / mL groups were significantly decreased.
[0336] Table 18 Changes in ROS levels in aged erythrocytes at 37°C after BZBS intervention with CD47 blockade
[0337]
[0338]
[0339] vs.Control:**P<0.01; vs.Model: ## P<0.01; vs.CD47 blocking Model: △△ P<0.01.
[0340] 3.5 Effect of BZBS on MDA in 37°C Aged Erythrocyte Model after CD47 Antibody Blocking
[0341] The experimental results are shown in Table 19. Compared with the IgG blocked control group, the MDA level of red blood cells in the IgG blocked model group was significantly increased. Compared with the IgG blocked model group, the MDA levels of red blood cells in the IgG blocked BZBS 100 μg / mL and 200 μg / mL groups were significantly decreased. Compared with the CD47 blocked control group, the MDA level of red blood cells in the CD47 blocked model group was significantly increased. Compared with the CD47 blocked model group, the MDA levels of red blood cells in the CD47 blocked BZBS 100 μg / mL and 200 μg / mL groups were significantly decreased.
[0342] Table 19 Changes in MDA levels of 37℃ aged erythrocytes after BZBS intervention with CD47 blockade
[0343]
[0344] vs.Control:*P<0.05,**P<0.01; vs.Model:##P<0.01; vs.CD47 blocking Model: △△P<0.01.
[0345] Example 10 Study on the influence of aging red blood cells on healthy red blood cells
[0346] 1 Experimental Materials
[0347] 1.1 Instruments and Equipment
[0348]
[0349] 1.2 Main Reagents
[0350]
[0351]
[0352] 2 Experimental methods
[0353] 2.1 Isolation of red blood cells
[0354] Take fresh EDTA-2K anticoagulated whole blood, centrifuge at 2000rpm for 5min to remove the upper solution such as plasma, add 10 times the volume of physiological sodium chloride solution to dilute, centrifuge at 2000rpm for 5min, remove the supernatant, take the red blood cells, repeat the above steps 2 to 3 times until the supernatant is colorless, remove the supernatant, take the deposited red blood cells, add an equal volume of red blood cell preservation solution, and place at 4℃ for use.
[0355] 2.2 Preparation of conditioned medium for aged erythrocytes
[0356] Take 5 ml of fresh packed red blood cells, add 5 ml of physiological sodium chloride solution, mix well, and place in a 37°C incubator for aging. After 48 hours, take out the aged red blood cells, centrifuge at 2000 rpm for 5 minutes, and take the supernatant. The supernatant is the aged red blood cell conditioned medium.
[0357] 2.3 Experimental Grouping
[0358] Take 6 ml of fresh packed red blood cells, wash them twice with physiological sodium chloride solution, and divide the red blood cells into the following two groups:
[0359] (1) Blank group (Control): Add 3 ml of physiological sodium chloride solution to 3 ml of red blood cells, mix well and place in a 4°C refrigerator for 48 h.
[0360] (2) Model group: 3 ml of conditioned medium containing aged red blood cells was added to 3 ml of red blood cells, mixed well, and placed in a 4°C refrigerator for 48 h.
[0361] 2.4 Index detection
[0362] 2.4.1Na + -K + -ATPase assay
[0363] After the experiment, centrifuge at 2000rpm for 5 minutes and discard the supernatant, take about 1mL of packed red blood cells, wash once with physiological sodium chloride solution; add hypotonic buffer (10mM Tris-Hcl) at a ratio of 1:10, mix well, place in a 4℃ environment for 20min, and then centrifuge at 4℃, 10000g for 10min, and discard the supernatant; add 10 times the volume of hypotonic buffer to the precipitate, mix well, and repeat centrifugation two or three times until the precipitate becomes milky white, discard the supernatant and the brown fibrin-like precipitate at the bottom of the centrifuge tube, and collect the white red blood cell membrane protein.
[0364] According to Na + -K + -ATPase activity detection kit instructions Determine the absorbance of each group of membrane protein samples at 636nm, Na + K + -ATPase activity calculation formula is as follows:
[0365]
[0366] C is the concentration of phosphorus standard solution, 0.02 μmol / mL; T is the reaction time, 10 min; V is the multiple of the total reaction volume and the sampling volume, that is, 7.8.
[0367] 2.4.2 Determination of ROS
[0368] After the experiment, centrifuge at 2000rpm for 5min and discard the supernatant. Take 10μL of packed red blood cells, add 90μL of serum-free DMEM / F12 medium to resuspend, dilute DCFH-DA with serum-free DMEM / F12 medium at 1:500 to a final concentration of 10μmol / L, and incubate in a cell culture incubator at 37℃ for 20min. Invert and mix every 3-5 minutes to allow the probe and cells to fully contact. Wash the cells once with serum-free cell culture medium, set the excitation wavelength to 488nm, the emission wavelength to 525nm, use red blood cells without probe added as blank control, and use flow cytometry to detect the percentage of positively labeled cells.
[0369] 2.4.3 Determination of phosphatidylserine (PS) externalization
[0370] After the experiment, centrifuge at 2000rpm for 5 minutes and discard the supernatant. Take about 10μL of packed red blood cells in a flow tube, wash twice with pre-cooled PBS, add 500μL 1×Binding Buffer to resuspend the cells, add 5μL Annexin V-FITC to each tube, vortex gently to mix, and incubate at room temperature in the dark for 5 minutes. Set the excitation wavelength to 488nm and the emission wavelength to 525nm, and use flow cytometry to detect the PS eversion level of each group of cells.
[0371] 2.4.4 Determination of MDA and 2,3-DPG
[0372] After the experiment, centrifuge at 2000rpm for 5min to discard the supernatant, take 50μL of packed red blood cells, add 200μL of pre-cooled double distilled water to hemolyze, mix well, add 100μL of 95% ethanol, oscillate for 30s, add 100μL of chloroform to extract for 1min, centrifuge at 3500rpm for 8min, the liquid is divided into three layers, the upper layer is the extract, the middle layer is the hemoglobin precipitate, and the lower layer is chloroform. If the supernatant is turbid, add a small amount of solid NaCl and centrifuge at 3500rpm for 5min to clarify. After the extract is taken out, it can be directly used to determine the MDA, 2,3-DPG levels and the protein concentration of the extract.
[0373] According to the instructions of the MDA kit, add the sample and the detection reagent respectively, mix well, keep warm in a 100℃ water bath for 60 minutes (cover tightly to prevent water loss), cool in an ice bath, and centrifuge at 10000g for 10 minutes at room temperature. Pipette 150μL of the supernatant into a 96-well plate, measure the absorbance of each sample at 450nm, 532nm and 600nm, and calculate △A450=A450 respectively. 测定 -A450 空白 , △A532=A532 测定 -A532 空白 , △A600=A600 测定 -A600 空白 The protein concentration (Cpr) of the extract was determined by the BCA method, and the MDA content was calculated according to the following formula:
[0374]
[0375] According to the instructions of the 2,3-DPG kit, add the sample and the detection reagent respectively. After the test, substitute the absorbance of the sample at 450nm into the standard curve to calculate the level of 2,3-DPG in the extract:
[0376]
[0377] 2.4.5 Determination of CD47 (flow cytometry)
[0378] After the experiment, centrifuge at 2000rpm for 5 minutes, take about 10μL of packed red blood cells into a flow tube, wash twice with PBS, add 90μL 1% BSA and 4μL FC end blocking antibody, and incubate at room temperature for 5-10min. Add 4μL CD47 antibody and incubate at 4℃ for 20min. Centrifuge at 2000rpm for 5min and discard the supernatant. Add 500μL PBS to each tube and wash twice, and finally resuspend with 500μL PBS, set the excitation wavelength to 488nm and the emission wavelength to 525nm, use red blood cells without CD47 antibody as blank control, and use flow cytometry to detect the expression level of CD47 on the red blood cell membrane of each group.
[0379] 2.4.6 Determination of Band3 and CD47 proteins
[0380] After the experiment, extract the red blood cell membrane protein according to the method in 4.2.4.1. Centrifuge at 18000rpm for 20min, remove the supernatant, add 100μL 2% SDS (containing 10μM PMSF) to lyse the membrane protein, centrifuge at room temperature (12000×g, 30 minutes) to take the supernatant, and use the BCA protein detection kit to determine the protein content in the supernatant. After adjusting the protein concentration, add 5× Loading Buffer, heat at 70℃ for 10min, and prepare the electrophoresis sample. Take an equal amount of protein sample and perform SDS-polyacrylamide gel electrophoresis (SDS-PAGE) in a 4-20% gel, transfer the protein to a nitrocellulose membrane (NC), block with blocking solution at 37℃, incubate with Band3, CD47, GAPDH primary antibodies (1:1000), wash with TBST, incubate with fluorescent secondary antibodies (1:5000 dilution), wash with TBST, and scan with the Odyssey protein imaging system.
[0381] 3 Experimental results
[0382] The experimental results are shown in Table 20, Table 21, and Appendix Figure 5 As shown in the figure, compared with the blank group, the levels of MDA, ROS and PS externalization in the model group were significantly increased, and the erythrocyte membrane Na + -K + -ATPase activity and CD47 expression level, as well as intracellular 2,3-DPG, Band3 and CD47 expression levels were significantly decreased.
[0383] Table 20 MDA, PS externalization, and Na in young erythrocytes after intervention with supernatant culture medium of aged erythrocytes + K + -Changes in ATPase activity, ROS, 2,3-DPG levels, and membrane surface CD47 expression
[0384]
[0385] vs.Control:*P<0.05,**P<0.01.
[0386] Table 21 Changes in CD47 and Band3 expression levels in young erythrocytes after intervention with supernatant culture medium of aged erythrocytes
[0387]
[0388] vs.Control:*P<0.05,**P<0.01.
[0389] Example 11 Study on the effect of the Chinese medicine composition of the present invention on red blood cells in the blood of 76 volunteers
[0390] 1 Experimental Materials
[0391] 1.1 Instruments and Equipment
[0392] Instrument Name Model or manufacturer Instrument Name Model or manufacturer Biological Safety Cabinets AIRTECH Vortex mixer IKA Autoclave ZEALWAY Benchtop centrifuge Flying Pigeon Constant temperature water bath Beijing Chemo Biotechnology Co., Ltd. Multifunctional ELISA reader BioTek Digital display dry heating system Labnet — —
[0393] 1.2 Main Reagents
[0394]
[0395] 2 Experimental methods
[0396] 2.1 Isolation of red blood cells
[0397] Take fresh EDTA-2K anticoagulated whole blood, centrifuge at 2000rpm for 5min to remove the upper solution such as plasma, add 10 times volume of physiological sodium chloride solution to dilute, centrifuge at 2000rpm for 5min, remove the supernatant, take the red blood cells, repeat the above steps 2 to 3 times until the supernatant is colorless, remove the supernatant, take the deposited red blood cells, and freeze them at -80℃.
[0398] 2.2 Experimental Grouping
[0399] (1) Before taking the drug: Red blood cells of volunteers who had not taken the test product BZBS
[0400] (2) After taking the drug: The red blood cells of volunteers after taking the test product BZBS orally for three months
[0401] The test sample BZBS is the content of the Chinese medicine composition capsule of the present invention prepared according to Example 1.
[0402] 2.3 Index detection
[0403] 2.3.1 Na + -K + -ATPase assay
[0404] After all clinical samples were collected, red blood cells were taken out from -80℃, and about 500μL was taken for detection after thawing; hypotonic buffer (10mM Tris-Hcl) was added at a ratio of 1:10, mixed evenly, and placed in a 4℃ environment for 20 minutes, and then centrifuged at 4℃, 10000g for 10min, and the supernatant was discarded; 10 times the volume of hypotonic buffer was added to the precipitate, mixed evenly, and centrifuged twice or three times until the precipitate turned milky white, the supernatant and the brown fibrin-like precipitate at the bottom of the centrifuge tube were discarded, and the white red blood cell membrane protein was collected.
[0405] According to Na + -K + -ATPase activity detection kit instructions Determine the absorbance of each group of membrane protein samples at 636nm, Na + -K + -ATPase activity calculation formula is as follows:
[0406]
[0407] C is the concentration of phosphorus standard solution, 0.02 μmol / mL; T is the reaction time, 10 min; V is the multiple of the total reaction volume and the sampling volume, that is, 7.8.
[0408] 2.3.2 Determination of MDA and 2,3-DPG
[0409] After all clinical samples are collected, red blood cells are taken out from -80℃, and about 200μL is taken for testing after thawing; 800μL pre-cooled double distilled water is added for hemolysis, mixed, 400μL of 95% ethanol is added, oscillated for 30s, 400μL of chloroform is added for extraction for 1min, centrifuged at 3500rpm for 8min, and the liquid is divided into three layers, the upper layer is the extract, the middle layer is the hemoglobin precipitate, and the lower layer is chloroform. If the supernatant is turbid, a small amount of solid NaCl can be added and centrifuged at 3500rpm for 5min to clarify it. After the extract is taken out, it can be directly used to determine the MDA, 2,3-DPG levels and the protein concentration of the extract.
[0410] According to the instructions of the MDA kit, add the sample and the detection reagent respectively, mix well, keep warm in a 100℃ water bath for 60 minutes (cover tightly to prevent water loss), cool in an ice bath, and centrifuge at 10000g for 10 minutes at room temperature. Pipette 150μL of the supernatant into a 96-well plate, measure the absorbance of each sample at 450nm, 532nm and 600nm, and calculate △A450=A450 respectively. 测定 -A450 空白 , △A532=A532 测定 -A532 空白 , △A600=A600测定 -A600 空白 The protein concentration (Cpr) of the extract was determined by the BCA method, and the MDA content was calculated according to the following formula:
[0411]
[0412] According to the instructions of the 2,3-DPG kit, add the sample and the detection reagent respectively. After the test, substitute the absorbance of the sample at 450nm into the standard curve to calculate the level of 2,3-DPG in the extract:
[0413]
[0414] 3 Experimental results
[0415] The experimental results are shown in Table 22. Compared with the control group before taking the medicine, the red blood cell membrane Na + -K + -ATPase activity and intracellular 2,3-DPG level increased significantly, while intracellular MDA level did not change significantly.
[0416] Table 22 Na of red blood cells before and after taking the medicine + -K + -ATPase, MDA, 2,3-DPG levels
[0417]
[0418] vs. before medication: **P<0.01.
[0419] Example 12 Study on the intervention effect of the Chinese medicine composition of the present invention and senescent red blood cells on the expression of SIRPα in macrophages 1 Experimental materials
[0420] 1.1 Instruments and Equipment
[0421]
[0422]
[0423] 1.2 Main Reagents
[0424]
[0425] 2 Experimental methods
[0426] 2.1 Preparation of main solutions
[0427] Preparation of test substance (BZBS) solution: Weigh an appropriate amount of BZBS powder, dissolve it in DMEM / F12 medium to prepare a 50 mg / mL stock solution, filter it with a 0.22 μM filter membrane, store it in aliquots at -20°C, and dilute it with physiological sodium chloride solution before use.
[0428] 2.2 Cell isolation and extraction
[0429] Quickly remove the cryovial containing THP-1 cells from liquid nitrogen, immediately put it in a 37℃ water bath to thaw quickly for about 1 minute, centrifuge it at 800rpm for 2 minutes, wipe the cryovial with 75% alcohol, move it to the clean bench, remove the cryopreservation solution, add 1640 culture medium containing 10% fetal bovine serum and 50μM β-mercaptoethanol, blow it evenly, transfer it to a culture dish, and culture it in a 37℃, 5% CO2 constant temperature cell culture incubator. When the cell growth reaches about 80% under an inverted microscope, subculture it at a ratio of 1:2 to 1:3. Take the cells with good growth after subculture for the experiment.
[0430] Preparation of senescent red blood cells: Take fresh EDTA-2K anticoagulated whole blood, centrifuge at 2000rpm for 5min to remove the upper solution such as plasma, add 10 times volume of physiological sodium chloride solution to dilute, centrifuge at 2000rpm for 5min, remove the supernatant, take red blood cells, repeat the above steps 2-3 times until the supernatant is colorless, remove the supernatant. Take 1mL of red blood cells, add 1mL of 1640 complete culture medium, and place in a 37℃ incubator for natural aging for 72h.
[0431] 2.3 Experimental Grouping
[0432] Take THP-1 cells in the logarithmic growth phase and inoculate them in a 3.5 cm glass-bottom dish or a six-well plate (cell density 3×10 5 / mL, 2mL / well), add 100ng / mL PMA to induce for 48h, discard the old culture medium after the cells adhere to the wall, and divide the cells into the following groups:
[0433] (1) Blank group (Control): Cultured with 1640 medium for 48 h.
[0434] (2) Test article group (BZBS): Culture was continued for 48 h using 1640 medium containing 200 μg / mL BZBS.
[0435] (3) Senescent erythrocytes: 2×10 6 The culture was continued for 48 h in 1640 medium containing 100 red blood cells / mL.
[0436] (4) Senescent erythrocytes plus test article group (Senescent erythrocytes + BZBS): 2×106 The cells were cultured in 1640 medium containing erythrocytes / mL and 200 μg / mL BZBS for 48 h.
[0437] After the experiment, the culture medium was discarded, and the cells were treated according to the following methods to detect the corresponding indicators.
[0438] 2.4 Index detection
[0439] 2.4.1 Laser confocal microscopy to detect the expression distribution of SIRPα on macrophage cell membrane
[0440] The experiment was carried out in a 3.5 cm glass-bottom dish. The cells were washed twice with pre-cooled PBS, fixed with 4% paraformaldehyde for 15 min, washed three times with PBS, permeabilized with 0.1% TritonX-100 for 5 min, washed three times with PBS, blocked with blocking solution (PBS containing 5% BSA and 10% goat serum) at room temperature for 1 h, incubated with SIRPα primary antibody (1:500, diluted in PBS containing 1% BSA and 3% goat serum) at 4°C overnight, washed three times with PBS, 5 min / time, incubated with fluorescent secondary antibody IgG (1:1000, diluted in PBS containing 1% BSA and 3% goat serum) at room temperature for 1 h, washed three times with PBS, 5 min / time, stained with Hoechst for 5 min, washed three times with PBS, 5 min / time, covered with antifade agent, and photographed with a laser confocal microscope.
[0441] 2.4.2 Detection of SIRPα expression level on macrophage cell membrane by flow cytometry
[0442] The experiment was carried out in a six-well plate. 200 μL of 0.25% trypsin was added to each well, and the cells were digested at 37°C for 3-5 min. After the cells fell off, 1 mL of 1640 culture medium was added to each well, and the cells were collected into flow tubes. The cells were washed twice with physiological sodium chloride solution, and 100 μL of SIRPα primary antibody (1:50, diluted in PBS containing 3% BSA) was added, and incubated at room temperature for 2 h. The cells were washed twice with physiological sodium chloride solution, and 100 μL of goat anti-rabbit fluorescent secondary antibody IgG (1:150, diluted in PBS containing 3% BSA) was added, and incubated at room temperature for 1 h. The cells were washed twice with physiological sodium chloride solution, and 500 μL of physiological sodium chloride solution was added to each group to resuspend the cells, and the cells were detected on a flow cytometer.
[0443] 2.4.3 Western Blot detection of SIRPα protein expression level in macrophages
[0444] The experiment was conducted using a six-well plate. The cells were washed twice with pre-cooled physiological sodium chloride solution. 100 μL of protein lysis buffer was added to each well. The cells were collected with a cell scraper and lysed on ice for 15 min. The cells were centrifuged at 12,000 rpm and 4°C for 30 min. The supernatant was aspirated as the protein sample. The protein concentration was determined by the BCA method. The loading buffer was added and placed in a metal bath at 100°C for 5 min for denaturation and aliquoted. The cells were stored in a -80°C refrigerator.
[0445] Western Blot detection: 30ug protein samples were taken from each group for sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The electrophoresis was stopped when the target protein approached the bottom of the separation gel; the gel was removed and the electrophoresis gel was placed in the transfer buffer for 20 minutes. Two filter papers of the same size as the gel were cut and placed in the transfer buffer for equilibration. The nitrocellulose membrane (NC membrane) was equilibrated in the buffer (PBS) for 20 minutes. The filter paper (negative electrode) was placed in the transfer instrument in the order of filter paper (negative electrode) - gel - NC membrane - filter paper (positive electrode). The membrane was transferred at 3mA / cm2 for 50 minutes, washed with TBS for 5 minutes, blocked with Odyssey special blocking solution at room temperature for 3 hours, cut the membrane according to the molecular weight of each protein, added antibodies diluted with blocking solution, and incubated at 4℃ overnight; washed with TBST for 8 minutes × 3 times, added secondary antibodies and incubated at room temperature in the dark for 40 minutes, and washed with TBST for 8 minutes × 3 times. The residual Tween-20 on the membrane was washed away with TBS, and the membrane was scanned and analyzed using an Odyssey scanner. The protein expression level was expressed as the ratio of the target protein to the internal reference GADPH.
[0446] 2.4.4 Detection of SIRPα mRNA expression level in macrophages by real-time fluorescence quantitative PCR
[0447] Six-well plates were used for the experiment, and total RNA was extracted according to the instructions of the Eastep Super total RNA extraction kit: 300 μL RNA lysis solution and 300 μL RNA diluent were added to each well and left at room temperature for 3 to 5 minutes; the mixture was collected in a 1.5 mL EP tube, 300 μL anhydrous ethanol solution was added, and the mixture was thoroughly mixed; the mixed solution was aspirated into a new centrifuge column, centrifuged at 12000 rpm for 1 min, and the filtrate was discarded; 600 μL RNA wash solution was added to the centrifuge column, centrifuged at 12000 rpm for 45 s, and the filtrate was discarded; 50 μL DNase I incubation solution was added to the center of the centrifuge column adsorption membrane and allowed to stand at room temperature for 15 min; 600 μL RNA wash solution was slowly added to the centrifuge column, centrifuged at 12000 rpm for 45 s, the filtrate was discarded, and the wash was repeated twice; the centrifuge column was placed on the elution tube, 55 μL nuclease-free water was slowly added to the center of the adsorption membrane, left at room temperature for 2 min, centrifuged at 12000 rpm for 1 min, and the RNA was stored in a -80°C refrigerator for later use.
[0448] RNA concentration and quality identification: Take 1 μL RNA sample and place it on the sample slot of NanoDrop 2000 ultra-micro spectrophotometer to detect the RNA OD260 / OD280 ratio. If the ratio is within the range of 1.8 to 2.1, it indicates that the RNA quality is high and reverse transcription can be performed.
[0449] The extracted RNA samples were reverse transcribed to synthesize cDNA according to the instructions of PrimeScript RT reagent Kit with gDNA Eraser. The reverse transcription system 1 is as follows:
[0450]
[0451] After the reaction system is prepared according to the table above, add it to a 0.5 ml nuclease-free micro-reaction tube, mix well and centrifuge instantly. Incubate the mixture at 42°C for 2 minutes, quickly remove it and place it on ice for 3-5 minutes to cool, and proceed to the next step. Reverse transcription system 2 is as follows:
[0452]
[0453] Reverse transcription reaction conditions: 37°C, 15 min; 85°C, 5 sec, 4°C storage. After the reverse transcription process is completed, cDNA is stored in a -80°C refrigerator for future use.
[0454] Using the synthesized cDNA as a template, perform real-time PCR according to the method in the TB Green Premix Ex Taq manual: The primer sequences are shown in Table 23. Prepare the PCR reaction mixture according to the following system and distribute it to each well, adding 2 μL of template to each well.
[0455]
[0456] Mix well and centrifuge, and perform RT-PCR reaction on a real-time fluorescence quantitative PCR instrument according to the predetermined reaction program. After the reaction is completed, Cyclophilin A is used as an internal reference gene control, and the relative expression level of the target mRNA to be tested is calculated by the 2-ΔΔCt method, and statistical analysis is performed.
[0457] Table 23 Primer sequences
[0458]
[0459] 3 Experimental results
[0460] 3.1BZBS significantly reduced the internalization of SIRPα in macrophage cell membrane
[0461] The experimental results are as attached Figure 6 As shown, compared with the blank group, the cell membrane SIRPα of the macrophages in the senescent red blood cell treatment group was significantly internalized; compared with the senescent red blood cell treatment group, the cell membrane SIRPα of the macrophages in the senescent red blood cell and BZBS co-treatment group was reduced.
[0462] 3.2BZBS significantly increased the expression level of SIRPα on the macrophage cell membrane
[0463] The experimental results are as attached Figure 7 As shown in Table 24, compared with the blank group, the expression level of cell membrane SIRPα of macrophages in the aging red blood cell treatment group was significantly decreased; compared with the aging red blood cell treatment group, the expression level of cell membrane SIRPα of macrophages in the aging red blood cell and BZBS co-treatment group was significantly increased.
[0464] Table 24 SIRPα expression levels of cell membranes in each group
[0465]
[0466] vs.Control: ** p<0.01; vs.Senescent erythrocytes: ## P<0.01.
[0467] 3.3 BZBS had no significant effect on the protein expression level of total SIRPα in macrophages
[0468] The experimental results are as attached Figure 8 As shown in Table 25, compared with the blank group, the SIRPα expression level of cells in each group had no significant change.
[0469] Table 25 Protein expression levels of total SIRPα in each group of cells
[0470]
[0471] 3.4 BZBS had no significant effect on the expression level of SIRPα mRNA in macrophages
[0472] The experimental results are shown in Table 26. Compared with the blank group, there was no significant change in the SIRPα mRNA expression level of cells in each group.
[0473] Table 26 Expression levels of SIRPα mRNA in each group of cells
[0474]
[0475] Example 13 Effect of the Chinese medicine composition of the present invention on the morphology of aged human red blood cells at 37°C
[0476] 1 Experimental Materials
[0477] 1.1 Instruments and Equipment
[0478] Instrument Name Model or manufacturer Instrument Name Model or manufacturer Clean bench AIRTECH Inverted microscope Zeiss Autoclave ZEALWAY Low temperature centrifuge Eppendorf <![CDATA[CO2 Incubator]]> Thermo Form Benchtop centrifuge Corning Floor standing centrifuge Beckman Automated cell counter Life technologies Vortex mixer IKA Scanning electron microscopy Hitachi Regulus8100
[0479] 1.2 Main Reagents
[0480]
[0481]
[0482] 2 Experimental methods
[0483] 2.1 Preparation of main solutions
[0484] (1) Preparation of β-nicotinamide mononucleotide (NMN): Weigh 3.34 mg of NMN and dissolve it in 1 mL of serum-free DMEM / F12 medium. Filter with a 0.22 μM filter membrane to prepare a 10 mM stock solution. Store in aliquots at -20°C and dilute with saline before use.
[0485] (2) Preparation of test sample (BZBS) solution: Weigh an appropriate amount of the contents of the Chinese medicine composition capsule of the present invention prepared according to Example 1, dissolve it in DMEM / F12 medium to prepare a 50 mg / mL stock solution, filter it with a 0.22 μM filter membrane, store it in aliquots at -20°C, and dilute it with physiological saline before use.
[0486] 2.2 Isolation of red blood cells
[0487] Take fresh EDTA-2K anticoagulated whole blood, centrifuge at 2000rpm for 5min to remove the upper solution such as plasma, add 10 times the volume of normal saline to dilute, centrifuge at 2000rpm for 5min, remove the supernatant, take the red blood cells, repeat the above steps 2 to 3 times until the supernatant is colorless, remove the supernatant, take the deposited red blood cells, add an equal volume of red blood cell preservation solution, and place at 4℃ for use.
[0488] 2.3 Experimental Grouping
[0489] Take the red blood cells and centrifuge them at 2000rpm for 5 minutes, remove the upper preservation solution, add 10 times the volume of normal saline, centrifuge at 2000rpm for 5 minutes to wash the cells, and then divide the cells into the following groups, with 1mL of packed red blood cells in each group:
[0490] (1) Blank group (Control): Add 1 mL of normal saline and culture at 4°C for 48 h.
[0491] (2) Model group: Add 1 mL of normal saline and culture at 37°C for 48 h.
[0492] (3) Test article group (BZBS): Add 1 mL of normal saline containing 400 μg / mL BZBS and culture at 37°C for 48 h.
[0493] (4) NMN group (NMN): 1 mL of physiological saline containing 100 μM NMN was added and cultured at 37°C for 48 h.
[0494] 2.4 Index detection
[0495] After the experiment, the samples were centrifuged at 2000 rpm for 5 minutes, the supernatant was discarded, the deposited red blood cells were washed 2 to 3 times with saline, and the samples were centrifuged at 2000 rpm for 5 minutes, the supernatant was discarded, and the hematocrit fluid of each group was obtained and sent to Hebei Medical University for sample processing and electron microscopy.
[0496] 3 Experimental results
[0497] The experimental results are as attached Fig. 9 As shown in the figure, compared with the blank group, the red blood cells in the model group were mostly irregular in shape, with cell adhesion, spine-like protrusions on the surface, and a large number of vesicles deposited outside the cells; compared with the model group, the cell morphology in the BZBS intervention group was more regular, the surface was relatively smooth, the spine-like protrusions were reduced, and the vesicle deposition outside the cells was significantly reduced.
[0498] 4 Summary
[0499] It can be seen from the experimental results that the Chinese medicine composition of the present invention can significantly improve the ultrastructure of naturally aged red blood cells at 37°C, and its effect is better than that of NMN.
[0500] Example 14 Effect of the Chinese medicine composition of the present invention on the intervention of sirtuin inhibitors on aging erythrocytes
[0501] 1 Experimental Materials
[0502] 1.1 Instruments and Equipment
[0503]
[0504] 1.2 Main Reagents
[0505]
[0506] 2 Experimental methods
[0507] 2.1 Preparation of main solution:
[0508] (1) Preparation of test sample (BZBS) solution: Weigh an appropriate amount of the contents of the Chinese medicine composition capsule of the present invention prepared according to Example 1, dissolve in DMEM / F12 medium to prepare a 50 mg / mL stock solution, filter with a 0.22 μM filter membrane, store in aliquots at -20°C, and dilute with physiological saline before use.
[0509] (2) Trichostatin A (TSA): The stock solution is dissolved in DMSO, the concentration is 5 mM, stored in aliquots at -20°C, and diluted with physiological saline before use.
[0510] 2.2 Isolation of red blood cells
[0511] Take fresh EDTA-2K anticoagulated whole blood, centrifuge at 2000rpm for 5min to remove the upper solution such as plasma, add 10 times the volume of normal saline to dilute, centrifuge at 2000rpm for 5min, remove the supernatant, take the red blood cells, repeat the above steps 2-3 times until the supernatant is colorless, remove the supernatant, take the deposited red blood cells, add an equal volume of red blood cell preservation solution, and place at 4℃ for use.
[0512] 2.3 Experimental Grouping
[0513] Take the red blood cells and centrifuge at 2000rpm for 5 minutes, remove the upper preservation solution, add 10 times the volume of normal saline and centrifuge at 2000rpm for 5 minutes to wash the cells, and then divide the cells into the following groups, with 1mL of packed red blood cells in each group:
[0514] (1) Blank group (Control): Add 1 mL of normal saline and culture at 4°C for 48 h.
[0515] (2) Model group: Add 1 mL of normal saline and culture at 37°C for 48 h.
[0516] (3) Test article group (BZBS): Add 1 mL of physiological saline containing 200 μg / mL BZBS and culture at 37°C for 48 h.
[0517] (4) Sirtuin inhibitor group (TSA): 1 mL of normal saline containing 5 μM Sirtuin inhibitor was added and cultured at 37°C for 48 h.
[0518] (5) Test article + sirtuin inhibitor group (BZBS + TSA): Add 1 mL of normal saline containing 5 μM sirtuin inhibitor and 200 μg / mL BZBS and culture at 37°C for 48 h.
[0519] 2.4 Index detection
[0520] (1) Detection of acetylated tubulin α-Tubulin (Ac-α-Tubulin) expression level (Western blot)
[0521] After the experiment, centrifuge at 2000rpm for 5min to discard the supernatant, wash with physiological saline three times, take 1.0mL of packed red blood cells, add hypotonic buffer (10mM Tris-Hcl) at a ratio of 1:10, mix well and place at 4℃ for 20min, centrifuge at 10000g for 10min at 4℃, aspirate the dark red supernatant, retain the precipitate, repeat adding hypotonic buffer and centrifuging to remove the supernatant 2-3 times until the precipitate becomes milky white, and collect the white or light pink red blood cell membrane.
[0522] Add 100 μL 2% SDS (containing 10 μM PMSF) to lyse membrane proteins, centrifuge at room temperature (12000×g, 30 min), take the supernatant, and use the BCA protein detection kit to determine the protein content in the supernatant. After adjusting the protein concentration, add 5× Loading Buffer, heat at 100°C for 10 min, and prepare electrophoresis samples. Take an equal amount of protein sample for SDS-polyacrylamide gel electrophoresis (SDS-PAGE) in a 4-20% gel, transfer the protein to a nitrocellulose membrane (NC), block with blocking solution at 37°C, incubate with Ac-α-Tubulin and GAPDH primary antibodies (1:1000), wash with TBST, incubate with fluorescent secondary antibodies (1:5000 dilution), wash with TBST, and scan with the Odyssey protein imaging system.
[0523] (2)Na + -K + -Detection of ATP(NKA) enzyme activity
[0524] The extraction method of red blood cell membrane is the same as 2.4.1, and the protein content in the supernatant is determined using the BCA protein detection kit. + -K+ -ATPase activity detection kit instructions Determine the absorbance of each group of membrane protein samples at 636nm, Na + -K + -ATPase activity calculation formula is as follows:
[0525]
[0526] Note: C is the concentration of phosphorus standard solution, 0.02 μmol / mL; T is the reaction time, 10 min; V is the multiple of the total reaction volume and the sampling volume, i.e. 7.8.
[0527] 3 Experimental results
[0528] (1) BZBS significantly reduced the expression level of Ac-α-Tubulin in the membrane of aged human erythrocytes
[0529] The experimental results are as attached Fig.10 As shown in Table 27, compared with the Control group, the level of erythrocyte membrane Ac-α-Tubulin in the Model group was significantly increased (P < 0.01); compared with the Model group, the level of erythrocyte membrane Ac-α-Tubulin in the BZBS group was significantly decreased (P < 0.05).
[0530] Table 27 Changes in the expression level of Ac-α-Tubulin in red blood cells of each group
[0531]
[0532] vs.Control:**P<0.01; vs.Model: # P<0.05.
[0533] (2) BZBS regulation of NKA activity in aging erythrocytes is closely related to the expression level of Ac-α-Tubulin
[0534] The experimental results are as attached Fig.11 As shown in Table 28, compared with the Control group, the erythrocyte NKA activity in the Model group was significantly decreased (P < 0.05); compared with the Model group, the erythrocyte NKA activity in the BZBS group was significantly increased (P < 0.01); compared with the BZBS group, the erythrocyte NKA activity in the BZBS+TSA group was significantly decreased (P < 0.01).
[0535] Table 28 Changes in erythrocyte NKA activity in each group
[0536]
[0537] vs.Control:# P<0.05; vs.Model:**P<0.01; vs.BZBS: ΔΔ P<0.01.
[0538] 4 Summary
[0539] It can be seen from the experimental results that the Chinese medicine composition of the present invention can improve the expression level of Ac-a-tubulin and NKA enzyme activity of naturally aged red blood cells at 37°C, and the regulation of NKA enzyme activity is closely related to the expression level of Ac-a-tubulin. Example 15 Effect of the Chinese medicine composition of the present invention on red blood cells after CD47 antibody blocking
[0540] 1 Experimental Materials
[0541] 1.1 Instruments and Equipment
[0542]
[0543]
[0544] 1.2 Main Reagents
[0545]
[0546] 2 Experimental methods
[0547] 2.1 Preparation of main solution:
[0548] Preparation of the test sample (BZBS) solution: Weigh an appropriate amount of the contents of the Chinese medicine composition capsule of the present invention prepared according to Example 1, dissolve it in DMEM / F12 medium to prepare a 50 mg / mL stock solution, filter it with a 0.22 μM filter membrane, store it in aliquots at -20°C, and dilute it with physiological saline before use.
[0549] 2.2 Isolation of red blood cells
[0550] Take fresh EDTA-2K anticoagulated whole blood, centrifuge at 2000rpm for 5min to remove the upper solution such as plasma, add 10 times the volume of normal saline to dilute, centrifuge at 2000rpm for 5min, remove the supernatant, take the red blood cells, repeat the above steps 2-3 times until the supernatant is colorless, remove the supernatant, take the deposited red blood cells, add an equal volume of red blood cell preservation solution, and place at 4℃ for use.
[0551] 2.3 IgG / CD47 antibody blocking
[0552] Take 1 mL of the above-mentioned cleaned packed red blood cells, add 1 mL of PBS (containing 1% BSA) containing 100 μg / mL CD47 or IgG antibody, incubate at 37°C for 1-2 h, centrifuge at 2000 rpm for 5 minutes, remove the supernatant, resuspend with 10 times the volume of normal saline, centrifuge at 2000 rpm for 5 minutes, remove the supernatant, repeat washing 3 times, and perform subsequent drug intervention and other treatments.
[0553] 2.4 Experimental Grouping
[0554] (1) IgG blocking control group (IgG Control): After IgG antibody blocking, the red blood cells were added with an equal volume of normal saline and placed at 4°C for 48 h;
[0555] (2) IgG blocking model group (IgG Model): After IgG antibody blocking, the red blood cells were added with an equal volume of normal saline and placed at 37°C for 48 h;
[0556] (3) IgG-blocked BZBS group (IgG BZBS): After IgG antibody blocking, the red blood cells were added with an equal volume of saline containing 400 μg / mL BZBS and placed at 37°C for 48 h;
[0557] (4) CD47 blocking control group (CD47 Control): Red blood cells blocked with CD47 antibody were added with an equal volume of normal saline and placed at 4°C for 48 h;
[0558] (5) CD47 blocking model group (CD47 Model): Red blood cells blocked with CD47 antibody were added with an equal volume of saline and placed at 37°C for 48 h;
[0559] (6) CD47-blocked BZBS group (CD47 BZBS): After CD47 antibody blocking, erythrocytes were added with an equal volume of saline containing 400 μg / mL BZBS and placed at 37°C for 48 h.
[0560] 2.5 Index detection
[0561] (1) Detection of Ac / Try / DeTry-α-Tubulin expression levels (Western blot)
[0562] After the experiment, centrifuge at 2000rpm for 5min to discard the supernatant, wash with physiological saline three times, take 0.5mL of packed red blood cells, add hypotonic buffer (10mM Tris-HCl) at a ratio of 1:10, mix well and place at 4℃ for 20min, centrifuge at 10000g for 10min at 4℃, aspirate the dark red supernatant, retain the precipitate, repeat adding hypotonic buffer and centrifuging to remove the supernatant two to three times until the precipitate becomes milky white, and collect the white or light pink red blood cell membrane.
[0563] Add 100 μL 2% SDS (containing 10 μM PMSF) to lyse membrane proteins, centrifuge at room temperature (12000×g, 30 min), take the supernatant, and use the BCA protein detection kit to determine the protein content in the supernatant. After adjusting the protein concentration, add 5× Loading Buffer, heat at 100°C for 10 min, and prepare electrophoresis samples. Take an equal amount of protein sample for SDS-polyacrylamide gel electrophoresis (SDS-PAGE) in a 4-20% gel, transfer the protein to a nitrocellulose membrane (NC), block with blocking solution at 37°C, incubate with Ac / Try / DeTry-α-Tubulin and GAPDH primary antibodies (1:1000), wash with TBST, incubate with fluorescent secondary antibodies (1:5000 dilution), wash with TBST, and scan with the Odyssey protein imaging system.
[0564] (2) NAD + Determination of
[0565] After the experiment, centrifuge at 2000 rpm for 5 min and discard the supernatant. After washing with saline three times, take 5 μL of packed red blood cells and add 300 μL of NAD + / NADH extract, gently blow to promote cell lysis, centrifuge at 12000rpm, 4℃ for 10min, take the supernatant for later use. Take 150μL of the supernatant in a centrifuge tube and heat at 60℃ for 30min to decompose NAD + , used for the detection of NADH levels. + / NADH detection kit instructions Determine the absorbance of each group of red blood cell samples at 450nm, NAD + The level calculation formula is as follows:
[0566] NAD + (μM)=NAD total -NADH
[0567] (3) Determination of NAMPT
[0568] After the experiment, centrifuge at 2000rpm for 5min and discard the supernatant. After washing with physiological saline for 3 times, take 10μL of packed red blood cells, wash 3 times with PBS, add 100μL of 0.05% glutaraldehyde to fix at room temperature for 10min, wash 3 times with PBS, permeabilize with 100μL of 0.1% TritonX-100 for 5min, wash 3 times with PBS, add 100μL of blocking solution to block at 37℃ for 1h, dilute NAMPT antibody (1:100) with conditional blocking solution, add 100μL of antibody to each and incubate overnight at 4℃, wash 3 times with PBS, dilute fluorescent secondary antibody (1:200) with conditional blocking solution, add 100μL of antibody to each and incubate for 1h, wash 3 times with PBS, take appropriate amount of red blood cells, add mounting medium and coverslip, and image with laser confocal microscope.
[0569] (4) SIRT2 enzyme activity assay
[0570] After the experiment, centrifuge at 2000rpm for 5min, discard the supernatant, wash with saline three times, take 10μL of packed red blood cells, add 300μL Tris-Hcl (10mM) to lyse the red blood cells, place at 4℃ for 20min, centrifuge at 10000g for 10min at 4℃, take the supernatant, and perform the test strictly according to the instructions of SIRT2 enzyme activity detection kit.
[0571] (5) Determination of HDAC6 activity level
[0572] After the experiment, centrifuge at 2000 rpm for 5 min, discard the supernatant, wash three times with saline, take 100 μL of packed red blood cells, add appropriate amount of HDAC6 lysis buffer, incubate on ice for 5 min, centrifuge at 16000 g for 10 min, take the supernatant, and operate strictly according to the instructions of the HDAC6 activity detection kit.
[0573] 3 Experimental results
[0574] (1) Effect of BZBS on the expression of tubulin in erythrocyte membranes aged at 37°C after CD47 antibody blocking
[0575] The experimental results are as attached Fig.12As shown in Table 29, IgG antibody blocking was used: the control group had no obvious expression of Ac / Try / DeTry-α-tubulin protein in erythrocytes, compared with the control group, the expression levels of DeTyr-α-tubulin and Total-α-tubulin in erythrocytes of the model group were significantly increased (P < 0.01), and compared with the model group, the expression levels of DeTyr-α-tubulin and Total-α-tubulin in erythrocytes of the BZBS group were significantly decreased (DeTyr: P < 0.01; Tot al: P<0.05); using CD47 antibody blocking: compared with the control group, the expression levels of Ac-α-tubulin, DeTyr-α-tubulin and Total-α-tubulin in erythrocytes of the model group were significantly increased (DeTyr: P<0.01; Ac&Total: P<0.05). Compared with the model group, the expression levels of Ac-α-tubulin, DeTyr-α-tubulin and Total-α-tubulin in erythrocytes of the BZBS group had no significant changes.
[0576] Table 29 Changes in the expression level of erythrocyte tubulin in each group
[0577]
[0578] vs.Control:**P<0.01,*P<0.05; vs.Model: # P<0.05, ## P<0.01.
[0579] (2) Effect of BZBS on NAD in aged erythrocytes at 37°C after blocking with CD47 antibody + The impact of level
[0580] The experimental results are as attached Fig.13 As shown in Table 30, IgG antibody blocking was used: Compared with the control group, the NAD + The level of NAD in erythrocytes in the BZBS group was significantly decreased (P<0.01). + The level of NAD in erythrocytes of the model group was significantly increased (P<0.01); CD47 antibody was used for blocking: compared with the control group, + The level of NAD in erythrocytes in the BZBS group was significantly decreased (P<0.01). + There was no significant change in levels.
[0581] Table 30 Red blood cell NAD in each group + Level changes
[0582]
[0583] vs.Control: ** P<0.01; vs. Model: ## P<0.01.
[0584] (3) Effect of BZBS on NAMPT expression in 37℃ aged erythrocytes after CD47 antibody blocking
[0585] The experimental results are as attached Fig.14 As shown, IgG antibody blocking was used: compared with the control group, the expression level of NAMPT in erythrocytes in the model group was significantly decreased, and compared with the model group, the expression level of NAMPT in erythrocytes in the BZBS group was significantly increased; CD47 antibody blocking was used: compared with the control group, the expression level of NAMPT in erythrocytes in the model group was significantly decreased, and compared with the model group, the expression level of NAMPT in erythrocytes in the BZBS group had no significant change.
[0586] (4) Effect of BZBS on SIRT2 activity of 37°C aged erythrocytes after CD47 antibody blocking
[0587] The experimental results are as attached Fig.15 As shown in Table 31, IgG antibody blocking was used: compared with the control group, the SIRT2 activity of erythrocytes in the model group was significantly decreased (P < 0.01), and compared with the model group, the SIRT2 activity of erythrocytes in the BZBS group was significantly increased (P < 0.01); CD47 antibody blocking was used: compared with the control group, the SIRT2 activity of erythrocytes in the model group was significantly decreased (P < 0.01), and compared with the model group, the SIRT2 activity of erythrocytes in the BZBS group had no significant change.
[0588] Table 31 Changes in erythrocyte SIRT2 activity in each group
[0589]
[0590] vs.Control:**P<0.01; vs.Model: ## P<0.01.
[0591] (5) Effect of BZBS on HDAC6 activity of 37°C aged erythrocytes after CD47 antibody blocking
[0592] The experimental results are as attached Fig.16As shown in Table 32, IgG antibody blocking was used: compared with the control group, the HDAC6 enzyme activity of erythrocytes in the model group was significantly decreased (P < 0.01), and compared with the model group, the HDAC6 enzyme activity of erythrocytes in the BZBS group was significantly increased (P < 0.05); CD47 antibody blocking was used: compared with the control group, the HDAC6 enzyme activity of erythrocytes in the model group was significantly decreased (P < 0.01), and compared with the model group, the HDAC6 enzyme activity of erythrocytes in the BZBS group had no significant change.
[0593] Table 32 Changes in HDAC activity of red blood cells in each group
[0594]
[0595] vs.Control:**P<0.01; vs.Model: # P<0.05.
[0596] 4 Summary
[0597] The experimental results show that after the red blood cell CD47 molecules were blocked by antibodies, the overall expression levels of Ac-α-tubulin and Total-α-tubulin of red blood cells in each group were significantly increased. The Chinese medicine composition of the present invention has an effect on the NAD of the naturally aged red blood cell membrane at 37°C. + , NAMPT level, SIRT2 and HDAC6 enzyme activity were significantly weakened or even disappeared, indicating that the Chinese medicine composition of the present invention improves the NAMPT and NAD of aging red blood cells. + The effects on the levels and activity of SIRT2 and HDAC6 are dependent on CD47.
[0598] Example 16 Study on the effect of the Chinese medicine composition (BZBS) of the present invention on 37°C aged human red blood cells
[0599] 1. Experimental Materials
[0600] 1.1 Instruments and Equipment
[0601]
[0602] 1.2 Main Reagents
[0603]
[0604] 2. Experimental Methods
[0605] 2.1 Preparation of main solution:
[0606] (1) β-Nicotinamide mononucleotide (NMN): Weigh 3.34 mg of NMN and dissolve it in 1 mL of serum-free DMEM / F12 medium. Filter with a 0.22 μM filter membrane to prepare a 10 mM stock solution. Store in aliquots at -20°C and dilute with physiological sodium chloride solution before use.
[0607] (2) Test solution (BZBS): Weigh an appropriate amount of BZBS powder and dissolve it in DMEM / F12 medium to prepare a 50 mg / mL stock solution. Filter with a 0.22 μM filter membrane, store in aliquots at -20°C, and dilute with physiological sodium chloride solution before use.
[0608] (3) Red blood cell fixative: Take 10 μL of 50% glutaraldehyde and dilute it to 10 mL with PBS to obtain the red blood cell fixative.
[0609] (4) Red blood cell permeabilization solution: Take 1 mL of Triton-X100 and dilute it to 50 mL with PBS to obtain a 2% Triton-X100 stock solution. Take 10 μL of the stock solution and dilute it to 200 μL with PBS to obtain the red blood cell permeabilization solution.
[0610] (5) Immunofluorescence blocking solution: Weigh 2.5 g BSA and dissolve it in 50 mL PBS to prepare 5% BSA. Take 9 mL 5% BSA and add 1 mL blocking sheep serum to prepare the blocking solution for immunofluorescence.
[0611] (6) Immunofluorescence blocking solution: Take 2 mL of 5% BSA and 0.33 mL of blocking sheep serum, and dilute to 10 mL with PBS to prepare immunofluorescence blocking solution.
[0612] 2.2 Separation of red blood cells:
[0613] Take fresh EDTA-2K anticoagulated whole blood, centrifuge at 2000rpm for 5min to remove plasma and other upper solutions, add 10 times volume of physiological sodium chloride solution to dilute, centrifuge at 2000rpm for 5min, remove the supernatant, take the red blood cells, repeat the above steps 2 to 3 times until the supernatant is colorless, remove the supernatant, take the deposited red blood cells, add an equal volume of red blood cell preservation solution, and place at 4℃ for use.
[0614] 2.3 Experimental Grouping
[0615] The red blood cells were centrifuged at 2000 rpm for 5 min, the upper preservation solution was removed, and 10 times the volume of physiological sodium chloride solution was added and centrifuged at 2000 rpm for 5 min to wash the cells.
[0616] 2.3.1 Hemoglobin (Hb) and acetylcholinesterase (AChE)
[0617] The cells were divided into the following groups, and 1 mL of packed red blood cells was taken from each group:
[0618] (1) Blank group (Control): Add 1 mL of physiological sodium chloride solution and culture at 4°C for 48 h.
[0619] (2) Model group: Add 1 mL of physiological sodium chloride solution and culture at 37°C for 48 h.
[0620] (3) Test article 100 μg / mL group (100): Add 1 mL of physiological sodium chloride solution containing 200 μg / mL BZBS and culture at 37°C for 48 h.
[0621] (4) Test article 200 μg / mL group (200): Add 1 mL of physiological sodium chloride solution containing 400 μg / mL BZBS and culture at 37°C for 48 h.
[0622] (5) Test article 300 μg / mL group (300): Add 1 mL of physiological sodium chloride solution containing 600 μg / mL BZBS and culture at 37°C for 48 h.
[0623] (6) NMN group (NMN): 1 mL of physiological sodium chloride solution containing 100 μM NMN was added and cultured at 37°C for 48 h.
[0624] 2.3.2 Erythrocyte exosome (EV) quantity and CD47 level of erythrocytes and erythrocytes
[0625] The cells were divided into the following three groups, with four time points set for each group, and 1 mL of packed red blood cells was collected at each time point in each group:
[0626] (1) Blank group (Control): Add 1 mL of physiological sodium chloride solution and culture at 4°C for 3 h, 6 h, 12 h, and 24 h.
[0627] (2) Model group: 1 mL of physiological sodium chloride solution was added and cultured at 37°C for 3 h, 6 h, 12 h, and 24 h.
[0628] (3) Test group (BZBS): 1 mL of physiological sodium chloride solution containing 400 μg / mL BZBS (final concentration 200 μg / mL) was added and cultured at 37°C for 3 h, 6 h, 12 h, and 24 h.
[0629] 2.3.3 Changes in red blood cell morphology and CD47 expression distribution (high-resolution laser confocal microscopy imaging)
[0630] The cells were divided into the following groups, with 1 mL of packed red blood cells in each group:
[0631] (1) Blank group (Control): Add 1 mL of physiological sodium chloride solution and place at 4°C for 48 h.
[0632] (2) Model group: Add 1 mL of physiological sodium chloride solution and culture at 37°C for 48 h.
[0633] (3) Test article group (BZBS): Add 1 mL of physiological sodium chloride solution containing 400 μg / mL BZBS (final concentration 200 μg / mL) and incubate at 37°C for 48 h.
[0634] 2.4 Index detection
[0635] 2.4.1 Hemoglobin (Hb)
[0636] After the experiment, centrifuge at 2000rpm for 5 minutes, discard the supernatant, add 1mL of physiological saline to resuspend, centrifuge at 2000rpm for 5 minutes, take 10μL of packed red blood cells and place them in a 1.5mL centrifuge tube, wash them three times with PBS, and add 2.5mL of Hb diluent application solution (preparation method: dilute Hb diluent stock solution with double distilled water at a ratio of 1:99) according to the instructions of the hemoglobin (Hb) kit, mix well, let stand for 5 minutes, wavelength 540nm, double distilled water zero, and measure the absorbance value of each well with an enzyme marker. Calculate the hemoglobin (Hb) content according to the following formula:
[0637] Hemoglobin (g / L) = (measured OD - blank OD) × 367.7
[0638] 2.4.2 Acetylcholinesterase (AChE)
[0639] After the experiment, centrifuge at 2000rpm for 5 minutes, discard the supernatant, add 1mL of physiological saline to resuspend, centrifuge at 2000rpm for 5 minutes, take 10μL of packed red blood cells and place them in a 1.5mL centrifuge tube, wash three times with PBS, and according to the instructions of the acetylcholinesterase (AChE) assay kit, take 10μL of packed red blood cells to 10mL of double distilled water, that is, dilute at 1:99, and mix thoroughly. Take 0.1mL of sample solution, add 0.5mL of substrate buffer and color development buffer respectively, react at 37℃ for 6min after mixing, add 0.03mL of inhibitor and 0.1mL of transparent agent respectively, mix thoroughly, let stand for 15min, wavelength 412nm, double distilled water zero, and measure the absorbance value of each well with an enzyme marker. Calculate the acetylcholinesterase (AChE) activity according to the following formula:
[0640]
[0641] C standard: standard concentration, 1 μmol / mL; N: dilution factor of the sample before testing.
[0642] 2.4.3 Erythrocyte exosome (EV) quantity
[0643] After the experiment, centrifuge at 2000rpm for 5min, and take about 1000μL supernatant from each red blood cell. Centrifuge at 2000g for 5min at 4℃ to remove the remaining cell precipitate. Take about 800μL supernatant and centrifuge at 29000g for 30min at 4℃. The precipitate is the red blood cell EV. Add 50μL PBS containing 1% BSA and 5μL Fc segment blocking antibody, incubate at room temperature for 10min, add 5μL CD235a antibody, and incubate at 4℃ for 3h. Add 500μL PBS to each tube for resuspending, centrifuge at 29000g for 30min at 4℃, discard the supernatant, and finally resuspend the precipitate with 500μL PBS into the flow tube. Set the excitation wavelength to 651nm and the emission wavelength to 660nm (APC). The red blood cell EV without CD235a antibody was used as the blank control, and the expression level of CD235a in the red blood cell EV of each group was detected by flow cytometry.
[0644] 1.2.4.4 Red blood cells and their exosomes CD47
[0645] After culturing for 3 h, 6 h, 12 h, and 24 h, the red blood cells of each group were centrifuged at 300 g for 8 min at 4 °C. The precipitate was the packed red blood cells, and the supernatant was used to collect red blood cell vesicles (EVs).
[0646] (1) Red blood cell CD47 detection: Take about 10 μL of packed red blood cells in a flow cytometer, wash twice with PBS, add 90 μL of PBS containing 1% BSA and 5 μL of Fc segment blocking antibody, and incubate at room temperature for 10 min. Add 4 μL of CD47 antibody and incubate at 4°C for 20 min. Centrifuge at 300g for 5 min at 4°C and discard the supernatant. Add 500 μL of PBS to each tube and wash twice. Finally, resuspend with 500 μL PBS. Red blood cells without CD47 antibody were used as blank controls. The CD47 expression level of red blood cells in each group was detected by flow cytometry.
[0647] (2) Detection of CD47 in erythrocyte exocytic vesicles: Centrifuge the erythrocyte supernatant at 2000g for 5 minutes at 4°C to remove the remaining cell precipitate. Aspirate the supernatant and centrifuge at 29000g for 30 minutes at 4°C. The precipitate is the erythrocyte EV. Add 50μL of PBS containing 1% BSA and 5μL of Fc segment blocking antibody and incubate at room temperature for 10 minutes. Add 4μCD47 antibody and 5μCD235a antibody and incubate at 4°C for 3 hours. Add 500μL PBS to each tube for resuspending, centrifuge at 29000g for 30 minutes at 4°C, discard the supernatant, and finally resuspend with 500μL PBS. Use flow cytometry to detect the expression level of CD47 in erythrocyte EVs of each group.
[0648] The statistical results were based on the total fluorescence level of CD47 in CD47+ erythrocytes and CD235a+CD47+ vesicles as the basis for evaluating the CD47 level.
[0649] 2.4.5 High-resolution imaging to observe red blood cell morphology
[0650] After the experiment, centrifuge at 2000rpm for 5min, discard the supernatant, add 1mL of physiological saline to resuspend, centrifuge at 2000rpm for 5min, take 10μL of packed red blood cells and place in a 1.5mL centrifuge tube, wash three times with PBS, add 100μL of fixative solution to fix at room temperature for 10min, wash three times with PBS, permeabilize with 100μL of permeabilization solution for 5min, wash three times with PBS, add 100μL of blocking solution to block at 37℃ for 1h, dilute CD47 antibody (1:200) with conditional blocking solution, add 100μL of antibody to incubate overnight, wash three times with PBS, dilute fluorescent secondary antibody (1:200) with conditional blocking solution, add 100μL of fluorescent secondary antibody to incubate for 1h, wash three times with PBS, take appropriate amount of red blood cells, add mounting medium and coverslip, and image with high-resolution laser confocal microscope.
[0651] 3. Experimental results
[0652] 3.1BZBS significantly increases Hb levels in 37℃ aged human erythrocytes
[0653] The experimental results are as attached Fig.17 As shown in Table 33, compared with the blank group, the Hb level of erythrocytes in the model group was significantly decreased; compared with the model group, the Hb level of erythrocytes in each BZBS group was significantly increased.
[0654] Table 33 Changes in Hb levels in erythrocytes of aged people treated with BZBS at 37℃
[0655]
[0656] vs.Control: ** P<0.01; vs. Model: # P<0.05, ## P<0.01.
[0657] 3.2BZBS significantly increases the AChE level in 37℃ aged human erythrocytes
[0658] The experimental results are as attached Fig.18 As shown in Table 34, compared with the blank group, the AChE level of erythrocytes in the model group was significantly decreased; compared with the model group, the Hb level of erythrocytes in each BZBS group was significantly increased in a dose-dependent manner.
[0659] Table 34 Changes of AChE levels in 37℃ aged human erythrocytes treated with BZBS
[0660]
[0661] vs.Control: ** P<0.01; vs. Model: ## P<0.01.
[0662] 3.3BZBS significantly reduces the release of EVs from aged human erythrocytes in a time-dependent manner
[0663] The experimental results are as attached Fig.19 As shown in Table 35, compared with the blank group, the number of EVs released from red blood cells in the model group at four time points was significantly increased and time-dependent; compared with the model group, the number of EVs released from red blood cells in the BZBS group at 6h, 12h, and 24h was significantly decreased.
[0664] Table 35 Time-effect relationship of the effect of BZBS on the number of vesicles released from aging human red blood cells
[0665]
[0666] vs.Control: ** P<0.01; vs. Model: ## P<0.01.
[0667] 3.4BZBS significantly inhibits the loss of CD47 in aging human erythrocytes in a time-dependent manner
[0668] The experimental results are as attached Fig. 20 , Attachment Fig.21 As shown in Table 36 and Table 37, compared with the blank group, the erythrocyte CD47 level in the model group was significantly decreased, and the erythrocyte exocytic vesicle CD47 level was significantly increased; compared with the model group, the erythrocyte CD47 level in the BZBS group was significantly increased, and the erythrocyte exocytic vesicle CD47 level was significantly decreased, and the changes in CD47 levels were time-dependent.
[0669] Table 36 Time-effect relationship of the effect of BZBS on CD47 level of aging human red blood cells
[0670]
[0671] vs.Control: ** P<0.01; vs. Model: ## P<0.01.
[0672] Table 37 Time-effect relationship of the effect of BZBS on the level of CD47 in exosomes of erythrocytes of aged humans
[0673]
[0674] vs.Control: ** P<0.01; vs. Model: ## P<0.01.
[0675] 3.5 High-resolution imaging observation: BZBS improves the cell morphology of aged human erythrocytes and significantly increases the level of cellular CD47
[0676] The experimental results are as attached Fig. 22 , Attachment Fig.23 As shown in Table 38, the red blood cells in the blank group were biconcave discs or spheres under the microscope, and the CD47 green fluorescence on the cell membrane was strong and basically evenly distributed; compared with the blank group, the red blood cells in the model group basically lost their disc-shaped appearance under the microscope, the cells shrank, and were generally irregularly spherical with many thorns, and the CD47 green fluorescence on the cell membrane was significantly weakened, and the cells were aggregated into a dot-like distribution; compared with the model group, the red blood cells in the BZBS group were mostly discs or spheres under the microscope with few thorns, and the CD47 green fluorescence on the cell membrane was significantly enhanced, and basically evenly distributed.
[0677] Table 38 Changes in CD47 fluorescence intensity of 37℃ aged human erythrocytes treated with BZBS
[0678]
[0679] vs.Control: ** P<0.01; vs. Model: ## P<0.01.
[0680] 4. Summary
[0681] In summary, BZBS can improve the morphology of 37°C aged human erythrocytes, significantly increase the Hb, CD47 expression and AchE enzyme activity levels of aged erythrocytes, and inhibit the release of aged erythrocyte vesicles and the loss of CD47 in a time-dependent manner. This indicates that BZBS can significantly improve the aging phenotype of erythrocytes.
[0682] Example 17 Study on the effect of the Chinese medicine composition (BZBS) of the present invention on the red blood cells of aging mice
[0683] 1 Experimental Materials
[0684] 1.1 Test and reference substances
[0685] Test sample (BZBS): capsules of the Chinese medicine composition of the present invention prepared according to Example 1, with a crude drug content of 2.86 g / g.
[0686] NMN: Bangtai Bioengineering Co., Ltd., batch number: BT05M122B004, specification: 500g / bag, purity ≥99.5%.
[0687] 1.2 Experimental animals
[0688] 1.2.1 Animal strain: C57BL / 6J mice.
[0689] 1.2.2 Animal grade: SPF grade.
[0690] 1.2.3 Animal sex, number and age: females, 160, 8 months old; females, 25, 8 weeks old.
[0691] 1.2.4 Animal source: Beijing Huafukang Biotechnology Co., Ltd. Laboratory Animal Use License No.: SCXK (Beijing) 2019-0008.
[0692] 1.2.5 Feeding conditions: Mice were caged, 5 mice / cage, in the New Drug Screening Department of Hebei Institute of Integrated Traditional Chinese and Western Medicine, with 12 hours of light per day, temperature of 20-25°C, and relative humidity of 40-70%.
[0693] 1.2.6 Quarantine process: The quarantine period for newly arrived animals is 3 to 7 days. During the quarantine period, the animals’ drinking water, food intake, health status, and signs of disease and death are observed.
[0694] 1.2.7 Adaptive feeding period feed: SPF mouse maintenance feed, provided by Beijing Huafukang Biotechnology Co., Ltd., feed production license number: Beijing Feed Certificate (2016) 06079.
[0695] Feed during the drug intervention period: Custom-made by Synergy Bioengineering Co., Ltd., feed production license number: Su Feed Certificate (2023)10035.
[0696] 1.2.8 Drinking water: Drink clean water prepared by the ROA50 experimental animal drinking water system, fill drinking water bottles for free drinking, and the water quality has been tested and meets the "Sanitary Standards for Drinking Water".
[0697] 1.2.9 Bedding: Sterilized wood shavings bedding, provided by Beijing Keao Xieli Feed Co., Ltd., production license number: SCXK(Beijing)2020-0010.
[0698] 1.3 Instruments and Equipment
[0699]
[0700]
[0701] 1.4 Main Reagents
[0702]
[0703] 2 Experimental methods
[0704] 2.1 Experimental Grouping:
[0705] After the adaptive feeding of young control mice (8 weeks old), relevant indicators were directly detected (Control). The 8-month-old mice were randomly divided into 4 groups, namely model group (Model), BZBS low-dose group (BL), BZBS high-dose group (BH), and positive control NMN group (NMN), with 40 mice in each group.
[0706] Feeding conditions: Mice were caged, 5 mice / cage, in the New Drug Screening Department of Hebei Institute of Integrated Traditional Chinese and Western Medicine, with 12 hours of light per day, temperature of 20-25°C, and relative humidity of 40-70%.
[0707] The treatments for each group are as follows:
[0708] (1) Model group: mice were given maintenance feed.
[0709] (2) BZBS low-dose group (BL): The mice were given synthetic feed containing BZBS at 1 g / kg / d.
[0710] (3) BZBS high-dose group (BH): The mice were given synthetic feed containing BZBS at 2 g / kg / d.
[0711] (4) Positive control NMN group (NMN): The mice were given synthetic feed containing NMN at 200 mg / kg / d.
[0712] 2.2 Model establishment and material collection method
[0713] According to the above grouping, when 8-month-old C57BL / 6J mice (≈18 years old in humans) were raised to 11 months (≈40 years old in humans), 15 months (≈55 years old in humans), 20 months (≈70 years old in humans), and 25 months (≈80 years old in humans), 10 mice were killed in each of the model group, BZBS low-dose group, BZBS high-dose group, and NMN group for the detection of corresponding indicators. When sampling, the eyeballs were removed and blood was collected into EDTA-2K anticoagulant tubes, mixed, and placed at 4°C for later use.
[0714] 2.3 Index detection
[0715] 2.3.1 ROS Level
[0716] Blood from mice aged 11, 15, 20, and 25 months was collected, centrifuged at 2000 rpm for 5 minutes, and the supernatant was discarded. 10 μL of packed red blood cells from each group was taken, and resuspended in 90 μL of serum-free DMEM / F12 medium, and 100 μL of serum-free DMEM / F12 medium containing the probe DCFH-DA (the probe DCFH-DA was diluted at a ratio of 1:500, and the final concentration was 10 μmol / L) was added and mixed, and incubated in a cell culture incubator at 37°C for 20 minutes. Invert and mix every 3-5 minutes to allow the probe and cells to fully contact. Wash the cells once with serum-free cell culture medium, set the excitation wavelength to 488 nm, the emission wavelength to 525 nm, and use red blood cells without the probe as the blank control. Use a BD flow cytometer to detect the percentage of cells positively labeled with the probe DCFH-DA.
[0717] 2.3.2 MDA and 2,3-DPG levels
[0718] Blood was collected from mice aged 11, 15, 20, and 25 months, centrifuged at 2000rpm for 5 minutes, and the supernatant was discarded. 50μL of packed red blood cells from each group were taken, and 200μL of pre-cooled double distilled water was added to hemolyze, and mixed; 100μL of 95% ethanol was added, and the mixture was shaken for 30s; 100μL of chloroform was added to extract for 1min, and centrifuged at 3500rpm for 8min. The liquid was divided into three layers, the upper layer was the extract, the middle layer was the hemoglobin precipitate, and the lower layer was chloroform. If the supernatant was turbid, a small amount of solid NaCl could be added, and the supernatant could be clarified by centrifugation at 3500rpm for 5min. After the extract was taken out, it was directly used for the determination of MDA, 2,3-DPG levels and protein concentrations in each group.
[0719] According to the instructions of the MDA kit, add the sample and the detection reagent respectively, mix well, keep warm in a 100℃ water bath for 60 minutes (cover tightly to prevent water loss), cool in an ice bath, and centrifuge at 10000g for 10 minutes at room temperature. Pipette 150μL of the supernatant into a 96-well plate, measure the absorbance of each sample at 450nm, 532nm and 600nm, and calculate △A450=A450 respectively. 测定 -A450 空白 , △A532=A532 测定 -A532 空白 , △A600=A600 测定 -A600 空白 The protein concentration (Cpr) of the extract was determined by the BCA method, and the MDA content was calculated according to the following formula:
[0720]
[0721] According to the instructions of the 2,3-DPG kit, add the sample and the detection reagent respectively. After the test, substitute the absorbance of the sample at 450nm into the standard curve to calculate the level of 2,3-DPG in the extract:
[0722]
[0723] 2.3.3Na + -K + -ATPase activity
[0724] Blood was collected from mice aged 11, 15, 20 and 25 months, centrifuged at 2000 rpm for 5 minutes, and about 1 mL of packed red blood cells was collected and washed once with physiological sodium chloride solution; hypotonic buffer (10 mM Tris-HCl) was added at a ratio of 1:10, mixed evenly, and placed in a 4°C environment for 20 minutes, and then centrifuged at 4°C, 10000 g for 10 minutes, and the supernatant was discarded; 10 times the volume of hypotonic buffer was added to the precipitate, mixed evenly, and centrifuged twice or three times until the precipitate turned milky white, the supernatant and the brown fibrin-like precipitate at the bottom of the centrifuge tube were discarded, and the white red blood cell membrane protein was collected.
[0725] According to Na + -K + -ATPase activity detection kit instructions Determine the absorbance of each group of membrane protein samples at 636nm, Na + -K + -ATPase activity calculation formula is as follows:
[0726]
[0727] C is the concentration of phosphorus standard solution, 0.02 μmol / mL; T is the reaction time, 10 min; V is the multiple of the total reaction volume and the sample volume, i.e. 7.8. 2.3.4 CD47 expression level (ELISA)
[0728] Take the red blood cell membranes of 11-month-old, 15-month-old, 20-month-old and 25-month-old mice stored in a -80°C refrigerator, centrifuge at 14,000 rpm for 5 minutes after thawing, and discard the supernatant. Wash the cell pellet twice with physiological sodium chloride solution, centrifuge at 14,000 rpm for 5 minutes each time, and discard the supernatant; add 200 μL of physiological saline to the precipitate. After ultrasonic disruption, take 100 μL for detection. Perform the test according to the instructions of the mouse CD47 ELISA kit, and use the BCA method to determine the protein concentration (Cpr). After the test, substitute the absorbance of the sample at 450 nm into the standard curve to calculate the level of CD47:
[0729]
[0730] 2.3.5 Erythrocyte exocytic vesicle quantity and vesicle CD47 level (flow cytometry)
[0731] Take the plasma of 11-month-old, 15-month-old, 20-month-old and 25-month-old mice stored in a -80℃ refrigerator, wait for it to thaw, and absorb 200μL of plasma, centrifuge at 7000rpm for 5min. Absorb about 100μL of supernatant from each group and centrifuge at 4℃, 29000g for 30min, and the precipitate is the EV in the plasma. Add 50μL of PBS containing 1% BSA and 5μL of Fc segment blocking antibody, incubate at room temperature for 10min. Add 5μL of TER-119 antibody and 5μL of CD47 antibody, incubate at 4℃ for 3h. Add 500μL of PBS to each tube for resuspending, centrifuge at 4℃, 29000g for 30min, discard the supernatant, and finally resuspend with 500μL PBS, set the excitation wavelength to 651nm, and the emission wavelength to 660nm (APC); set the excitation wavelength to 488nm, and the emission wavelength to 525nm (FITC). EVs without TER-119 and CD47 antibodies were used as blank controls; EVs with only TER-119 antibodies were used as APC single staining; EVs with only CD47 antibodies were used as FITC single staining. Flow cytometry was used to detect the expression levels of TER-119 and CD47 in EVs of each group.
[0732] 2.3.6 Red blood cell CD47 level (flow cytometry)
[0733] About 10 μL of packed red blood cells from 25-month-old mice were taken for experiment, and the method was the same as that in Example 16.
[0734] 2.3.7 Hemoglobin (Hb)
[0735] About 10 μL of packed red blood cells from 25-month-old mice were taken for experiment, and the method was the same as that in Example 16.
[0736] 2.3.8 Acetylcholinesterase (AChE)
[0737] About 10 μL of packed red blood cells from 25-month-old mice were taken for experiment, and the method was the same as that in Example 16.
[0738] 2.3.9 Ps eversion (Ps)
[0739] After the experiment, centrifuge at 2000rpm for 5 minutes, take about 10μL of packed red blood cells from 25-month-old mice into a flow tube, wash twice with pre-cooled PBS, add 500μL 1×Binding Buffer to resuspend the cells, add 5μL Annexin V-FITC to each tube, gently vortex to mix, and incubate at room temperature in the dark for 5 minutes. Set the excitation wavelength to 488nm and the emission wavelength to 525nm, and use flow cytometry to detect the PS eversion level of each group of cells.
[0740] 2.3.10 Ca2+ ion
[0741] Take about 10 μL of packed red blood cells from 25-month-old mice, add 90 μL PBS to resuspend, dilute Fluo-4 fluorescent probe with PBS at 1:500 to a final concentration of 2 μM, and incubate in a cell culture incubator at 37°C for 30 minutes. Invert and mix every 3 to 5 minutes to allow the probe and cells to fully contact. Wash the cells twice with PBS, set the excitation wavelength to 488 nm, the emission wavelength to 525 nm, use red blood cells without probe added as blank control, and use flow cytometry to detect the percentage of positively labeled cells.
[0742] 3 Experimental results
[0743] 3.1 BZBS significantly reduced the levels of MDA and ROS in erythrocytes of aged mice
[0744] The experimental results are as attached Fig.24 , Attachment Fig.25 As shown in Tables 39 and 40, compared with the aging model group mice, the erythrocyte ROS level of 25-month-old BZBS group mice was significantly decreased, and the erythrocyte MDA level of 15-month-, 20-month- and 25-month-old BZBS group mice was significantly decreased, and the erythrocyte MDA and ROS levels of the mice in the BZBS groups at each age and dose decreased in a time- and dose-dependent manner.
[0745] Table 39 Changes in ROS levels in erythrocytes of aging mice treated with BZBS
[0746]
[0747] vs.Model: ## P<0.01.
[0748] Table 40 Changes in the level of MDA in erythrocytes of aging mice treated with BZBS
[0749]
[0750] vs.Model: # P<0.05, ## P<0.01.
[0751] 3.2 BZBS significantly reduces 2,3-DPG levels in erythrocytes of aged mice
[0752] The experimental results are as attached Fig.26 As shown in Table 41, compared with the mice in the aging model group, the erythrocyte 2,3-DPG level of the 15-month and 20-month-old BZBS group mice was significantly decreased, and the decrease was time- and dose-dependent.
[0753] Table 41 Changes in 2,3-DPG levels in red blood cells of aging mice treated with BZBS
[0754]
[0755] vs.Model: # P<0.05, ## P<0.01.
[0756] 3.3 BZBS significantly increased the Na of erythrocytes in aged mice + -K + -ATPase levels
[0757] The experimental results are as attached Fig. 27 As shown in Table 42, compared with the aging model group mice, the red blood cell Na + -K + -ATPase level was significantly increased, and the red blood cell Na + -K + -ATPase levels increased in a time- and dose-dependent manner.
[0758] Table 42 BZBS intervention on erythrocyte Na in aging mice + -K + -Changes in ATPase levels
[0759]
[0760] vs.Model: ## P<0.01.
[0761] 3.4BZBS significantly upregulated the expression level of CD47 in erythrocytes of aged mice (ELISA)
[0762] The experimental results are as attached Fig.28 As shown in Table 43, compared with the 8-month-old mouse group, the CD47 expression levels on the erythrocyte membrane of the aging model mice at 11, 15, 20, and 25 months of age were significantly decreased; compared with the aging model group mice, the CD47 levels on the erythrocytes of the 15-month-old BZBS high-dose group and the 25-month-old BZBS groups were significantly increased, and the increase was time- and dose-dependent.
[0763] Table 43 Changes in CD47 levels in erythrocytes of aging mice treated with BZBS
[0764]
[0765] vs.8months:* P<0.05, ** P<0.01; vs. Model: # P<0.05, ## P<0.01.
[0766] 3.5 BZBS significantly reduced the number of EVs released from erythrocytes and the level of vesicle CD47 in aged mice (flow cytometry)
[0767] The experimental results are as attached Fig.29 As shown in Table 44, compared with the 8-month-old mouse group, the number of EVs released from plasma erythrocytes in the aging model mice at 11, 15, 20, and 25 months of age was significantly increased; compared with the aging model group mice, the number of EVs released from plasma erythrocytes in the BZBS groups at 15, 20, and 25 months of age was significantly decreased, and the decrease was dose-dependent.
[0768] Table 44 Changes in the number of EVs released from red blood cells in aging mice treated with BZBS
[0769]
[0770] vs.8months: ** P<0.01; vs. Model: # P<0.05, ## P<0.01.
[0771] The experimental results are as attached Fig.30 As shown in Table 45, compared with the 8-month-old mouse group, the CD47 level on the plasma erythrocyte exocytic vesicles of the aging model mice at 15, 20, and 25 months of age was significantly increased; compared with the aging model group mice, the CD47 level on the plasma erythrocyte exocytic vesicles of the BZBS groups at 15, 20, and 25 months of age was significantly decreased, and the decrease was dose-dependent.
[0772] Table 45 Changes in the level of CD47 in erythrocyte exocytic vesicles in aging mice treated with BZBS
[0773]
[0774] vs.8months: ** P<0.01; vs. Model: ## P<0.01.
[0775] 3.6BZBS significantly increased the level of CD47 in erythrocytes of 25-month-old aged mice (flow cytometry)
[0776] The experimental results are as attached Fig.31As shown in Table 46, compared with the control group, the CD47 level on the erythrocyte membrane of 25-month-old aging model mice was significantly decreased; compared with the model group, the CD47 level on the erythrocyte membrane of mice in the low- and high-dose BZBS groups was significantly increased, and the increase was dose-dependent.
[0777] Table 46 Changes in the level of red blood cell CD47 in 25-month-old mice treated with BZBS
[0778]
[0779] vs.Control: ** P<0.01; vs. Model: ## P<0.01.
[0780] 3.7BZBS significantly increased the hemoglobin (Hb) level in erythrocytes of 25-month-old aged mice
[0781] The experimental results are as attached Fig.32 As shown in Table 47, compared with the control group, the erythrocyte Hb level of 25-month-old aging model mice was significantly decreased; compared with the model group, the erythrocyte Hb level of mice in the high-dose BZBS group was significantly increased.
[0782] Table 47 Changes in red blood cell Hb levels in aging mice treated with BZBS
[0783]
[0784] vs.Control:**P<0.01; vs.Model: # P<0.05, ## P<0.01.
[0785] 3.8 BZBS significantly increased the level of acetylcholinesterase (AChE) in erythrocytes of 25-month-old aged mice
[0786] The experimental results are as attached Fig.33 As shown in Table 48, compared with the control group, the AChE level in the erythrocytes of the 25-month-old aging model mice was significantly decreased; compared with the model group, the AChE level in the erythrocytes of the mice in the high-dose BZBS group was significantly increased.
[0787] Table 48 Changes in AChE levels in erythrocytes of aging mice treated with BZBS
[0788]
[0789] vs.Control:*P<0.05; vs.Model: # P<0.05.
[0790] 3.9 BZBS significantly reduced the level of Ps externalization (Ps) in erythrocytes of 25-month-old aged mice
[0791] The experimental results are as attached Fig.34 As shown in Table 49, compared with the control group, the level of PS externalization of erythrocytes in 25-month-old aging model mice was significantly increased; compared with the model group, the level of PS externalization of erythrocytes in mice in the low- and high-dose BZBS groups was significantly decreased, and the decrease was dose-dependent.
[0792] Table 49 Changes in PS externalization levels of erythrocytes in aging mice treated with BZBS
[0793]
[0794] vs.Control:**P<0.01; vs.Model: ## P<0.01.
[0795] 3.10 BZBS significantly reduced the Ca2+ level in erythrocytes of 25-month-old aged mice 2+ Ion Level
[0796] The experimental results are as attached Fig.35 As shown in Table 50, compared with the control group, the red blood cell Ca 2+ ion levels were significantly increased; compared with the model group, the red blood cell Ca 2+ The ion levels were significantly decreased in a dose-dependent manner.
[0797] Table 50 BZBS intervention on erythrocyte Ca in aging mice 2+ Level changes
[0798]
[0799] vs.Control:**P<0.01; vs.Model: # P<0.05, ## P<0.01.
[0800] 4 Summary
[0801] In summary, the Chinese medicine composition of the present invention can significantly reduce the MDA, ROS, Ca2+, Ps externalization and 2,3-DPG levels of erythrocytes in aged mice, significantly inhibit the release of erythrocyte vesicles and the loss of erythrocyte CD47, and significantly promote the increase of erythrocyte Hb levels, Na+-K+-ATPase and AChE enzyme activity levels. This shows that BZBS can significantly improve the aging phenotype of erythrocytes.
[0802] Example 18 Study on the changes in aging phenotype of red blood cells in 109 volunteers before and after taking the Chinese medicine composition (BZBS) of the present invention
[0803] 1 Experimental Materials
[0804] 1.1 Instruments and Equipment
[0805] Instrument Name Model or manufacturer Instrument Name Model or manufacturer Clean bench AIRTECH Inverted microscope Zeiss Autoclave ZEALWAY Low temperature centrifuge Eppendorf <![CDATA[CO2 Incubator]]> Thermo Form Benchtop centrifuge Corning Multifunctional ELISA reader BioTek Flow cytometry BD Floor standing centrifuge Beckman Constant temperature water bath Beijing Chemo Biotechnology Co., Ltd. Biological Safety Cabinets AIRTECH Vortex mixer IKA Digital display dry heating system Labnet
[0806] 1.2 Main Reagents
[0807]
[0808] 2 Experimental methods
[0809] 2.1 Isolation of red blood cells
[0810] Take fresh EDTA-2K anticoagulated whole blood, centrifuge at 2000rpm for 5min to remove the upper solution such as plasma, add 10 times volume of physiological sodium chloride solution to dilute, centrifuge at 2000rpm for 5min, remove the supernatant, take the red blood cells, repeat the above steps 2 to 3 times until the supernatant is colorless, remove the supernatant, take the deposited red blood cells, and freeze them at -80℃.
[0811] 2.2 Experimental Grouping
[0812] (1) Before Administration: Red blood cells from volunteers who had not taken BZBS.
[0813] (2) After Administration: Red blood cells of volunteers after oral administration of BZBS for three months.
[0814] 2.3 Index detection
[0815] 2.3.1 Na + -K + -ATPase assay
[0816] After all clinical samples are collected, take out the red blood cells from -80℃, thaw and take about 500μL for detection. The detection method is shown in 2.2.4.3.
[0817] 2.3.2 Red blood cell CD47 levels
[0818] After all clinical samples were collected, the red blood cell membrane was removed from -80℃, and after thawing, it was centrifuged at 14000rpm for 5 minutes, and the supernatant was discarded. It was washed twice with physiological sodium chloride solution, centrifuged at 14000rpm for 5 minutes each time, and the supernatant was discarded; 200μL of physiological saline was added to the precipitate. After ultrasonic disruption, 100μL was taken for detection. The detection was performed according to the instructions of the Human CD47 ELISA kit. After the detection, the absorbance of the sample at 450nm was substituted into the standard curve to calculate the level of CD47.
[0819] 2.3.3 Erythrocyte exosome (EV) quantity and vesicle CD47 level
[0820] After the experiment, take out the plasma from the -80℃ refrigerator, wait for it to thaw, take out 200μL of plasma, and centrifuge at 7000rpm for 5min. Take about 100μL of supernatant and centrifuge at 4℃, 29000g for 30 minutes. The precipitate is the EV in the plasma. Add 50μL 1% BSA and 5μL Fc segment blocking antibody, incubate at room temperature for 10min. Add 5μL CD235a antibody and 5μLCD47 antibody, incubate at 4℃ for 3h. Add 500μL PBS to each tube and resuspend, centrifuge at 4℃, 29000g for 30min, discard the supernatant, and finally resuspend with 500μL PBS, set the excitation wavelength to 651nm, the emission wavelength to 660nm (APC); set the excitation wavelength to 488nm, and the emission wavelength to 525nm (FITC). EVs without CD235a and CD47 antibodies were used as blank controls; EVs with only CD235a antibodies were used as APC single staining; EVs with only CD47 antibodies were used as FITC single staining. Flow cytometry was used to detect the expression levels of CD235a and CD47 in EVs of each group.
[0821] 3 Experimental results
[0822] 3.1BZBS significantly increased human red blood cell Na + -K + -ATPase activity
[0823] The experimental results are as attached Fig.36 As shown in Table 51, compared with the volunteers before taking the medicine, the red blood cell membrane Na of the volunteers after taking BZBS for 3 months + -K + -ATPase activity was significantly increased.
[0824] Table 51 Changes in Na+-K+-ATPase activity of human red blood cells treated with BZBS
[0825]
[0826] vs.Before: **P<0.01.
[0827] 3.2BZBS significantly increases the level of CD47 in human red blood cells
[0828] The experimental results are as attached Fig.37 As shown in Table 52, compared with the volunteers before taking the medicine, the red blood cell CD47 level of the volunteers increased significantly after taking BZBS for 3 months.
[0829] Table 52 Changes of human red blood cell CD47 levels after BZBS intervention
[0830]
[0831] vs.Before: * P<0.05.
[0832] 3.3BZBS significantly reduced the number of human red blood cell vesicles released and the level of vesicle CD47
[0833] The experimental results are as attached Fig.38 , Attachment Fig.39 As shown in Table 53 and Table 54, compared with the volunteers before taking the medicine, the number of red blood cell vesicles released by the volunteers was significantly reduced and the CD47 level on the vesicles was significantly reduced after taking BZBS for 3 months.
[0834] Table 53 Changes in the number of vesicle release from human red blood cells after BZBS intervention
[0835]
[0836] vs.Before: ** P<0.01.
[0837] Table 54 Changes of CD47 levels on exosomes of human red blood cells during BZBS intervention
[0838]
[0839] vs.Before: ** P<0.01.
[0840] 4 Summary
[0841] In summary, taking BZBS for 3 months can significantly increase the red blood cell Na in volunteers' blood. + -K + -ATPase activity and CD47 level, and significantly reduced the number of erythrocyte vesicle release and vesicle CD47 level, indicating that BZBS can significantly improve the aging phenotype of erythrocytes.
[0842] Example 19 Study on the effect of the Chinese medicine composition (BZBS) of the present application on human red blood cells after CD47 antibody blocking
[0843] 1 Experimental Materials
[0844] 1.1 Instruments and Equipment
[0845] Instrument Name Model or manufacturer Instrument Name Model or manufacturer Biological Safety Cabinets AIRTECH Vortex mixer IKA Autoclave ZEALWAY Benchtop centrifuge Flying Pigeon Flow cytometry BD Multifunctional ELISA reader BioTek Constant temperature water bath Beijing Chemo Biotechnology Co., Ltd. Digital display dry heating system Labnet
[0846] 1.2 Main Reagents
[0847]
[0848] 2 Experimental methods
[0849] 2.1 Preparation of main solution:
[0850] Test solution: Weigh an appropriate amount of BZBS powder and dissolve it in DMEM / F12 medium to prepare a 50 mg / mL stock solution. Filter with a 0.22 μM filter membrane, store in aliquots at -20°C, and dilute with physiological sodium chloride solution before use.
[0851] 2.2 Isolation of red blood cells
[0852] Take fresh EDTA-2K anticoagulated whole blood, centrifuge at 2000rpm for 5min to remove the upper solution such as plasma, add 10 times the volume of physiological sodium chloride solution to dilute, centrifuge at 2000rpm for 5min, remove the supernatant, take the red blood cells, repeat the above steps 2-3 times until the supernatant is colorless, remove the supernatant, take the deposited red blood cells, add an equal volume of red blood cell preservation solution, and place at 4℃ for use.
[0853] 2.3 IgG / CD47 antibody blocking
[0854] Take 1 mL of the above-mentioned cleaned packed red blood cells, add 1 mL of PBS (containing 1% BSA) containing 100 μg / mL CD47 or IgG antibody, incubate at 37°C for 1-2 h, centrifuge at 2000 rpm for 5 minutes, remove the supernatant, resuspend with 10 times the volume of physiological sodium chloride solution, centrifuge at 2000 rpm for 5 minutes, remove the supernatant, repeat washing 3 times, and perform subsequent drug intervention and other treatments.
[0855] 2.4 Experimental Grouping
[0856] (1) IgG blocking control group (IgG Control): After IgG antibody blocking, the red blood cells were added with an equal volume of physiological sodium chloride solution and placed at 4°C for 48 h.
[0857] (2) IgG blocking model group (IgG Model): After IgG antibody blocking, the red blood cells were added with an equal volume of physiological sodium chloride solution and placed at 37°C for 48 h.
[0858] (3) IgG-blocked BZBS group (IgG BZBS): After IgG antibody blocking, the red blood cells were added with an equal volume of physiological sodium chloride solution containing 400 μg / mL BZBS and placed at 37°C for 48 h.
[0859] (4) CD47 blocking control group (CD47 Control): After CD47 antibody blocking, the red blood cells were added with an equal volume of physiological sodium chloride solution and placed at 4°C for 48 h.
[0860] (5) CD47 blocking model group (CD47 Model): Red blood cells blocked with CD47 antibody were added with an equal volume of physiological sodium chloride solution and placed at 37°C for 48 h.
[0861] (6) CD47-blocked BZBS group (CD47 BZBS): After CD47 antibody blocking, erythrocytes were added with an equal volume of physiological sodium chloride solution containing 400 μg / mL BZBS and placed at 37°C for 48 h.
[0862] 3 indicators detection
[0863] 3.1 Phosphatidylserine (PS) externalization level
[0864] Same as Example 17.
[0865] 3.2 Hemoglobin (Hb)
[0866] Same as Example 16.
[0867] 3.3 Acetylcholinesterase (AChE)
[0868] Same as Example 16.
[0869] 3.4 Release of EVs
[0870] Same as Example 16.
[0871] 3 Experimental results
[0872] 3.1BZBS significantly reduced the PS externalization level of 37℃ aged human erythrocyte membrane before and after CD47 antibody blocking
[0873] The experimental results are as attached Fig.40As shown in Table 55, compared with the IgG blocked control group, the PS externalization level of erythrocytes in the IgG blocked model group was significantly increased, and compared with the IgG blocked model group, the PS externalization level of erythrocytes in the IgG blocked BZBS group was significantly decreased; compared with the CD47 blocked control group, the PS externalization level of erythrocytes in the CD47 blocked model group was significantly increased, and compared with the CD47 blocked model group, the PS externalization level of erythrocytes in the CD47 blocked BZBS group was significantly decreased.
[0874] Table 55 Changes in Ps externalization levels of 37℃ aged human erythrocytes after BZBS intervention with CD47 blockade
[0875]
[0876] vs.Control: ** P<0.01; vs. Model: # P<0.05, ## P<0.01.
[0877] 3.2BZBS significantly reduced the Hb level of 37℃ aged human erythrocyte membrane before and after CD47 antibody blocking
[0878] The experimental results are as attached Fig.41 As shown in Table 56, compared with the IgG blocking control group, the Hb level of red blood cells in the IgG blocking model group was significantly decreased, and compared with the IgG blocking model group, the Hb level of red blood cells in the IgG blocking BZBS group was significantly increased; compared with the CD47 blocking control group, the Hb level of red blood cells in the CD47 blocking model group was significantly decreased, and compared with the CD47 blocking model group, the Hb level of red blood cells in the CD47 blocking BZBS group was significantly increased.
[0879] Table 56 Changes in Hb levels in 37℃ aged human erythrocytes after BZBS intervention with CD47 blockade
[0880]
[0881] vs.Control: * P<0.05, ** P<0.01; vs. Model: # P<0.05, ## P<0.01.
[0882] 3.3BZBS significantly reduced the AChE level of 37℃ aged human erythrocyte membrane before and after CD47 antibody blocking
[0883] The experimental results are as follows Fig.42As shown in Table 57, compared with the IgG blocking control group, the AChE level of erythrocytes in the IgG blocking model group was significantly decreased, and compared with the IgG blocking model group, the AChE level of erythrocytes in the IgG blocking BZBS group was significantly increased; compared with the CD47 blocking control group, the AChE level of erythrocytes in the CD47 blocking model group was significantly decreased, and compared with the CD47 blocking model group, the AChE level of erythrocytes in the CD47 blocking BZBS group was significantly increased.
[0884] Table 57 Changes in AChE levels in aged human erythrocytes at 37°C after BZBS intervention with CD47 blockade
[0885]
[0886] vs.Control: ** P<0.01; vs. Model: ## P<0.01.
[0887] 3.4BZBS significantly reduced the release of EVs from 37°C aged human erythrocytes before and after CD47 antibody blocking
[0888] The experimental results are as attached Fig.43 As shown in Table 58, compared with the IgG blocked control group, the release level of EVs from red blood cells in the IgG blocked model group was significantly increased, and compared with the IgG blocked model group, the release level of EVs from red blood cells in the IgG blocked BZBS group was significantly decreased; compared with the CD47 blocked control group, the release level of EVs from red blood cells in the CD47 blocked model group was significantly increased, and compared with the CD47 blocked model group, the release level of EVs from red blood cells in the CD47 blocked BZBS group was significantly decreased.
[0889] Table 58 Changes in the number of EVs released from 37℃ aged human erythrocytes after BZBS intervention with CD47 blockade
[0890]
[0891] vs.Control: ** P<0.01; vs. Model: ## P<0.01.
[0892] 4 Summary
[0893] In summary, combined with the experimental data obtained in the previous study, after CD47 antibody blocked the erythrocyte CD47 molecule, the Chinese medicine composition of the present invention can still significantly reduce the levels of PS eversion and EV release of 37°C aged human erythrocytes, and significantly increase the levels of Hb and AChE, only affecting the Na of 37°C aged human erythrocyte membranes. + -K+ -The improvement effect of ATPase activity was significantly weakened or even disappeared.
[0894] Example 20 Study on the effect of the Chinese medicine composition (BZBS) of the present invention on the phenotype of red blood cells after induced vesicle release 1 Experimental materials
[0895] 1.1 Instruments and Equipment
[0896]
[0897] 1.2 Main Reagents
[0898]
[0899]
[0900] 2 Experimental methods
[0901] 2.1 Preparation of main solutions
[0902] (1) Test solution: Weigh an appropriate amount of BZBS powder and dissolve it in DMEM / F12 medium to prepare a 50 mg / mL stock solution. Filter with a 0.22 μM filter membrane, store in aliquots at -20°C, and dilute with physiological sodium chloride solution before use.
[0903] (2) Adiponectin stock solution: Take 100 μg of adiponectin and add 167 μL of deionized water to prepare a 600 μg / mL stock solution.
[0904] (3) Red blood cell fixative: Take 10 μL of 50% glutaraldehyde and dilute it to 10 mL with PBS to obtain the red blood cell fixative.
[0905] (4) Red blood cell permeabilization solution: Take 1 mL of Triton-X100 and dilute it to 50 mL with PBS to obtain a 2% Triton-X100 stock solution. Take 10 μL of the stock solution and dilute it to 200 μL with PBS to obtain the red blood cell permeabilization solution.
[0906] (5) Immunofluorescence blocking solution: Weigh 2.5 g BSA and dissolve it in 50 mL PBS to prepare 5% BSA. Take 9 mL 5% BSA and add 1 mL blocking sheep serum to prepare the blocking solution for immunofluorescence.
[0907] (6) Immunofluorescence blocking solution: Take 2 mL of 5% BSA, add 0.33 mL of blocking sheep serum, and dilute to 10 mL with PBS to prepare immunofluorescence blocking solution.
[0908] 2.2 Cell isolation and extraction
[0909] Take fresh EDTA-2K anticoagulated whole blood, centrifuge at 2000rpm for 5min to remove the upper solution such as plasma, add 10 times the volume of physiological sodium chloride solution to dilute, centrifuge at 2000rpm for 5min, remove the supernatant, take the red blood cells, repeat the above steps 2 to 3 times until the supernatant is colorless, remove the supernatant, take the deposited red blood cells, add an equal volume of red blood cell preservation solution, and place at 4℃ for use.
[0910] 2.3 Experimental Grouping
[0911] Take 3 mL of packed red blood cells, wash them twice with saline and divide the cells into the following groups:
[0912] (1) Blank group (Control): 1 mL of packed red blood cells was added with 0.5 mL of physiological sodium chloride solution.
[0913] (2) Adiponectin group (APN): 1 mL of packed red blood cells was added with 0.5 mL of physiological sodium chloride solution with a final concentration of 20 μg / mL adiponectin.
[0914] (3) BZBS group (BZBS): 1 mL of packed red blood cells was added with 0.5 mL of physiological sodium chloride solution with a final concentration of 20 μg / mL adiponectin and 200 μg / mL BZBS.
[0915] After being placed at 4°C for 24 h, the incubation supernatant and cells were collected, processed according to the following methods, and the corresponding indexes were tested.
[0916] 2.4 Index detection
[0917] 2.4.1 Determination of MDA and 2,3-DPG
[0918] Same as Example 17.
[0919] 2.4.2 Determination of ROS
[0920] Same as Example 17.
[0921] 2.4.3 High-resolution imaging to observe red blood cell morphology
[0922] Same as Example 16.
[0923] 3 Experimental results
[0924] 3.1BZBS can significantly reduce the 2,3-DPG level of erythrocytes induced by vesicle promoter
[0925] The experimental results are as attached Fig.44 As shown in Table 59, compared with the blank group, the 2,3-DPG level of red blood cells in the adiponectin group was significantly increased; compared with the adiponectin group, the 2,3-DPG level of red blood cells in the BZBS group was significantly decreased.
[0926] Table 59 Changes in erythrocyte 2,3-DPG levels after BZBS intervention with vesicle promoter induction
[0927]
[0928] vs.Control: ** P<0.01; vs. Model: ## P<0.01.
[0929] 3.2BZBS can significantly reduce the MDA level of erythrocytes induced by vesicle promoter
[0930] The experimental results are as attached Fig.45 As shown in Table 60, compared with the blank group, the MDA level of erythrocytes in the adiponectin group was significantly increased; compared with the adiponectin group, the MDA level of erythrocytes in the BZBS group was significantly decreased.
[0931] Table 60 Changes in erythrocyte MDA levels after BZBS intervention with vesicle promoter induction
[0932]
[0933]
[0934] vs.Control: ** P<0.01; vs. Model: ## P<0.01.
[0935] 3.3BZBS can significantly reduce the level of ROS in erythrocytes induced by vesicle promoter
[0936] The experimental results are as attached Fig.46 As shown in Table 61, compared with the blank group, the level of erythrocyte ROS in the adiponectin group was significantly increased; compared with the adiponectin group, the level of erythrocyte ROS in the BZBS group was significantly decreased.
[0937] Table 61 Changes in ROS levels in erythrocytes after BZBS intervention with vesicle promoter induction
[0938]
[0939] vs.Control: ** P<0.01; vs. Model: ## P<0.01.
[0940] 3.4 High-resolution imaging observation: BZBS improves the cell morphology of erythrocytes induced by vesicle promoters and significantly increases the level of cell CD47
[0941] The experimental results are as attached Fig.47 , Attachment Fig.48 As shown in Table 62, the red blood cells in the blank group were biconcave discs or spheres under the microscope, the CD47 green fluorescence on the cell membrane was strong and basically evenly distributed; compared with the blank group, the red blood cells in the adiponectin group mostly lost their disc-like appearance and were generally irregular spheres with thorns, the CD47 green fluorescence on the cell membrane was weak, and the cells were aggregated into point-like distribution; compared with the adiponectin group, there were no obvious changes in the red blood cell morphology and CD47 green fluorescence on the cell membrane in the BZBS group.
[0942] Table 62 Changes in red blood cell CD47 fluorescence intensity after BZBS intervention vesicle promoter induction
[0943]
[0944] vs.Control: ** P<0.01.
[0945] 4 Summary
[0946] In summary, after adiponectin-induced erythrocyte vesicle release, the Chinese medicine composition of the present invention can significantly reduce the levels of MDA, 2,3-DPG and ROS in the adiponectin-induced erythrocyte model.
[0947] Example 21 Study on the effect of the Chinese medicine composition (BZBS) of the present invention on the phenotype of erythrocytes released from mice 1 Experimental materials
[0948] 1.1 Test sample
[0949] BZBS, the contents of the capsule prepared according to Example 1, has a crude drug content of 2.86 g / g.
[0950] 1.2 Experimental animals
[0951] 1.2.1 Animal strain: C57BL / 6J mice.
[0952] 1.2.2 Animal grade: SPF grade.
[0953] 1.2.3 Animal sex, number and age: Male, 36, 8 weeks old.
[0954] 1.2.4 Animal source: Beijing Huafukang Biotechnology Co., Ltd. Laboratory Animal Use License No.: SCXK (Beijing) 2019-0008.
[0955] 1.2.5 Feeding conditions: Mice were caged, 5 mice / cage, in the New Drug Screening Department of Hebei Institute of Integrated Traditional Chinese and Western Medicine, with 12 hours of light per day, temperature of 20-25°C, and relative humidity of 40-70%.
[0956] 1.2.6 Quarantine process: The quarantine period for newly arrived animals is 3 to 7 days. During the quarantine period, the animals’ drinking water, food intake, health status, and signs of disease and death are observed.
[0957] 1.2.7 Adaptive feeding period feed: SPF mouse maintenance feed, provided by Beijing Huafukang Biotechnology Co., Ltd., feed production license number: Beijing Feed Certificate (2016) 06079.
[0958] 1.2.8 Drinking water: Drink clean water prepared by the ROA50 experimental animal drinking water system, fill drinking water bottles for free drinking, and the water quality has been tested and meets the "Sanitary Standards for Drinking Water".
[0959] 1.2.9 Bedding: Sterilized wood shavings bedding, provided by Beijing Keao Xieli Feed Co., Ltd., production license number: SCXK(Beijing)2020-0010.
[0960] 1.3 Instruments and Equipment
[0961] Instrument Name Model or manufacturer Instrument Name Model or manufacturer Clean bench AIRTECH Flow cytometry BD Autoclave ZEALWAY Low temperature centrifuge Eppendorf Multifunctional ELISA reader BioTek Benchtop centrifuge Flying Pigeon Constant temperature water bath Beijing Chemo Biotechnology Co., Ltd. Digital display dry heating system Labnet
[0962] 1.4 Main Reagents
[0963]
[0964] 2 Experimental methods
[0965] 2.1 Preparation of main solutions
[0966] (1) 0.5% CMC solution: Weigh 0.5 g of sodium carboxymethyl cellulose and dissolve it in 100 mL of water. Mix well and stir at 4°C overnight.
[0967] (2) Test solution: Weigh an appropriate amount of BZBS powder and dissolve it in 0.5% CMC solution to prepare a 400 mg / mL solution. Ultrasonicate for 20 min to promote dissolution and prepare it before use.
[0968] (3) Adiponectin solution: Add 250 μL of physiological sodium chloride solution to each adiponectin (100 μg) to prepare a 400 mg / mL solution.
[0969] 2.2 Experimental Grouping
[0970] After the adaptive feeding, the 8-week-old mice were randomly divided into 3 groups, namely, blank group (Control), adiponectin group (APN), and BZBS group (BZBS), with 12 mice in each group. The treatment of each group was as follows:
[0971] (1) Blank group (Control): 0.5% CMC solution 200 μL / mouse was gavaged daily for 7 consecutive days, and physiological sodium chloride solution 100 μL / mouse was injected into the tail vein on the 7th day.
[0972] (2) Adiponectin group (APN): 0.5% CMC solution 200 μL / mouse was administered intragastrically every day for 7 consecutive days. On the 7th day, adiponectin solution 100 μL / mouse was injected into the tail vein.
[0973] (3) BZBS group (BZBS): mice were gavaged with 200 μL of BZBS solution per mouse every day for 7 consecutive days, and adiponectin solution was injected into the tail vein at 100 μL per mouse on the 7th day.
[0974] 24 hours after adiponectin injection, the eyeballs were removed and blood was collected into EDTA-2K anticoagulant tubes, mixed, and stored at 4°C for later use.
[0975] Attached Fig.49 A schematic diagram of the administration and sampling time for the study of the effect of BZBS on adiponectin-induced mouse erythrocyte phenotype is given.
[0976] 2.3 Index detection
[0977] 2.3.1Na + -K + -ATPase assay
[0978] Same as Example 17.
[0979] 2.3.2 Determination of MDA and 2,3-DPG
[0980] Same as Example 17.
[0981] 2.3.3 Acetylcholinesterase (AChE)
[0982] Same as Example 16.
[0983] 2.3.4 Determination of phosphatidylserine (PS) externalization
[0984] Same as Example 19.
[0985] 2.3.5 Determination of ROS
[0986] Same as Example 17.
[0987] 2.3.6 Calcium ion (Ca 2+ )
[0988] Same as Example 17.
[0989] 2.3.7 Hemoglobin (Hb)
[0990] Same as Example 16.
[0991] 2.3.8 Erythrocyte exocytic vesicle count
[0992] Same as Example 17.
[0993] 2.3.9 Red blood cell CD47 level (flow cytometry)
[0994] Same as Example 16.
[0995] 2.3.10 Erythrocyte exocytic vesicle quantity and vesicle CD47 level (flow cytometry)
[0996] Same as Example 17.
[0997] 3 Experimental results
[0998] 3.1BZBS can significantly reduce the 2,3-DPG level in mouse erythrocytes after vesicle promoter induction
[0999] The experimental results are as attached Fig.50 As shown in Table 63, compared with the blank group, the 2,3-DPG level of the red blood cells of the mice in the adiponectin group was significantly increased; compared with the adiponectin group, the 2,3-DPG level of the red blood cells of the mice in the Bazi Bu Shen group was significantly decreased.
[1000] Table 63 Changes in 2,3-DPG levels in mouse erythrocytes after BZBS intervention with vesicle promoter induction
[1001]
[1002] vs.Control: ** P<0.01; vs. Model: ## P<0.01.
[1003] 3.2BZBS can significantly reduce the MDA level of mouse erythrocytes induced by vesicle promoter
[1004] The experimental results are as attached Fig.51 As shown in Table 64, compared with the blank group, the MDA level of erythrocytes of mice in the adiponectin group was significantly increased; compared with the adiponectin group, the MDA level of erythrocytes of mice in the BZBS group was significantly decreased.
[1005] Table 64 Changes in the level of MDA in red blood cells of mice after intervention with vesicle promoter induced by Bazi
[1006]
[1007] vs.Control: ** P<0.01; vs. Model: ## P<0.01.
[1008] 3.3BZBS can still significantly reduce the PS externalization level of mouse erythrocytes induced by vesicle promoter
[1009] The experimental results are as attached Fig.52 As shown in Table 65, compared with the blank group, the level of PS externalization of erythrocytes in the mice in the adiponectin group was significantly increased; compared with the adiponectin group, the level of PS externalization of erythrocytes in the mice in the BZBS group was significantly decreased.
[1010] Table 65 Changes in the level of PS externalization in mouse erythrocytes after BZBS intervention vesicle promoter induction
[1011]
[1012] vs.Control: * P<0.05; vs. Model: ## P<0.01.
[1013] 4 Summary
[1014] In summary, after adiponectin induced the release of mouse erythrocyte vesicles in vivo, the Chinese medicine composition of the present invention can still significantly reduce the levels of MDA, 2,3-DPG and PS in the adiponectin-induced mouse erythrocyte model, which is similar to the effect of the Chinese medicine composition of the present invention after adiponectin induced the release of mouse erythrocyte vesicles in vitro.
[1015] in conclusion
[1016] In summary, the Chinese medicine composition of the present invention has a significant improvement effect on the survival activity of the H2O2-induced damaged human erythrocyte model, can significantly reduce the MDA and ROS levels of the model cells, and significantly increase the Na + -K + -ATPase activity, 2,3-DPG level and the total amount of membrane protein.
[1017] The Chinese medicine composition of the present invention can significantly improve the ultrastructure of naturally aged red blood cells at 37°C, and its effect is better than that of NMN. The Chinese medicine composition of the present invention can improve the expression level of Ac-a-tubulin and NKA enzyme activity of naturally aged red blood cells at 37°C, and the regulation of NKA enzyme activity is closely related to the expression level of Ac-a-tubulin. After the red blood cell CD47 molecules were blocked with antibodies, the overall expression levels of Ac-α-tubulin and Total-α-tubulin of red blood cells in each group were significantly increased. The Chinese medicine composition of the present invention has an effect on the NAD of naturally aged red blood cell membranes at 37°C. +, NAMPT level, SIRT2 and HDAC6 enzyme activity were significantly weakened or even disappeared, indicating that the Chinese medicine composition of the present invention improves the NAMPT and NAD of aging red blood cells. + The effects on the levels and activity of SIRT2 and HDAC6 are dependent on CD47.
[1018] The Chinese medicine composition of the present invention can also significantly reduce the MDA, ROS and Ca of 37°C aged model red blood cells. 2+ Levels, significantly increased Na + -K + -ATPase activity, significantly improving 2,3-DPG levels; it can significantly upregulate the expression levels of Band3 and CD47 proteins in 37°C aged erythrocyte membranes, reduce the clustering of Band3 proteins, significantly increase the activity of cell membrane aminophospholipid translocases, and reduce the level of phosphatidylserine (PS) externalization.
[1019] After CD47 antibody blocks the CD47 molecule on the erythrocyte membrane, the Chinese medicine composition of the present invention can still significantly reduce the ROS, MDA, and Ca in the 37°C aged erythrocyte model. 2+ However, the Na + -K + -The improvement effect of ATPase activity was significantly weakened or even disappeared.
[1020] The supernatant of aged erythrocytes can significantly increase the levels of ROS, MDA and PS externalization in young erythrocytes, and reduce the Na + -K + -ATPase activity, 2,3-DPG, Band3 and CD47 levels.
[1021] After taking the Chinese medicine composition of the present invention for 3 months, the red blood cell Na in the blood can be significantly increased. + -K + -ATPase activity and 2,3-DPG levels.
[1022] Senescent erythrocytes can promote the translocation of SIRPα on the macrophage cell membrane into the cell, thereby reducing the expression level of SIRPα on the cell membrane; the Chinese medicine composition of the present invention can reduce the intracellular translocation of SIRPα on the macrophage membrane induced by senescent erythrocytes by delaying the senescence of erythrocytes, thereby increasing the expression level of SIRPα on the cell membrane, but has no significant effect on the expression levels of total SIRPα protein and mRNA.
[1023] In vitro experimental studies and in vivo experiments on mice have shown that the Chinese medicine composition of the present invention can significantly improve the aging phenotype of red blood cells. Clinical experiments have further shown that the Chinese medicine composition of the present invention can significantly improve the aging phenotype of red blood cells.
Claims
1. Use of a traditional Chinese medicine composition in the preparation of a drug for improving red blood cell function, the traditional Chinese medicine composition being prepared from the following raw materials in parts by weight: 150-350 parts of Cuscuta seeds, 100-200 parts of Lycium barbarum, 30-60 parts of Schisandra chinensis, 20-50 parts of Cnidium monnieri, 20-50 parts of Rosa laevigatae, 20-50 parts of Allium tuberosum, 20-50 parts of Morinda officinalis, 20-50 parts of Cistanche deserticola, 30-60 parts of Rehmannia root, 20-50 parts of Cyathula officinalis, 40-100 parts of Epimedium, 20-50 parts of Rubus idaeus, 15-35 parts of Ginseng, 10-25 parts of Pilose antler, 15-35 parts of Hippocampus, and 15-35 parts of Toosendan fruit.
2. The use according to claim 1, It is characterized in that The Chinese medicine composition is prepared from the following raw materials in parts by weight: 150 parts of Cuscuta seeds, 200 parts of Lycium barbarum, 30 parts of Schisandra chinensis, 50 parts of Cnidium monnieri, 20 parts of Rosa laevigata, 20 parts of Allium tuberosum seeds, 50 parts of Morinda officinalis, 20 parts of Cistanche deserticola, 30 parts of Rehmannia root, 50 parts of Cyathula officinalis, 40 parts of Epimedium, 50 parts of Rubus idaeus, 15 parts of Ginseng, 25 parts of Pilose antler, 15 parts of Hippocampus, and 35 parts of Toosendan fruit.
3. The use according to claim 1, It is characterized in that The Chinese medicine composition is prepared from the following raw materials in parts by weight: 350 parts of Cuscuta seeds, 100 parts of Lycium barbarum, 60 parts of Schisandra chinensis, 20 parts of Cnidium monnieri, 50 parts of Rosa laevigata fruit, 50 parts of Allium tuberosum seed, 20 parts of Morinda officinalis, 50 parts of Cistanche deserticola, 60 parts of Rehmannia root, 20 parts of Cyathula officinalis, 100 parts of Epimedium, 20 parts of Rubus idaeus, 35 parts of Ginseng, 10 parts of Pilose antler, 35 parts of Hippocampus, and 15 parts of Toosendan fruit.
4. The use according to claim 1, It is characterized in that The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 250 parts of Cuscuta seeds, 138 parts of Lycium barbarum, 46 parts of Schisandra chinensis, 35 parts of Cnidium monnieri, 35 parts of Rosa laevigata, 35 parts of Allium tuberosum, 35 parts of Morinda officinalis, 35 parts of Cistanche deserticola, 46 parts of Rehmannia root, 35 parts of Cyathula officinalis, 70 parts of Epimedium, 35 parts of Rubus idaeus, 25 parts of Ginseng, 16 parts of Pilose antler, 21 parts of Hippocampus, and 23 parts of Toosendan fruit.
5. The use according to claim 1, It is characterized in that The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 250 parts of Cuscuta seeds, 150 parts of Lycium barbarum, 45 parts of Schisandra chinensis, 30 parts of Cnidium monnieri, 30 parts of Rosa laevigata fruit, 30 parts of Allium tuberosum seed, 30 parts of Morinda officinalis, 30 parts of Cistanche deserticola, 45 parts of Rehmannia root, 30 parts of Cyathula officinalis, 70 parts of Epimedium, 30 parts of Rubus idaeus, 20 parts of Ginseng, 19 parts of Pilose antler, 20 parts of Hippocampus, and 20 parts of Toosendan fruit.
6. The use according to any one of claims 1 to 5, It is characterized in that The dosage form of the medicine is decoction, capsule, tablet, granule, powder or pill.
7. A method for preparing the capsule according to claim 6, It is characterized in that The preparation method comprises the following steps: a. Weigh Cnidium monnieri, Cuscuta chinensis, Schisandra chinensis, and Epimedium brevicornum according to the proportion, add 6-10 times the amount of 70% ethanol, reflux extraction 1-3 times, each time for 1-3 hours, filter, combine the filtrate, and recover ethanol under reduced pressure until there is no alcohol taste, to obtain an alcohol extract; b. Combine the medicinal material residue after alcohol extraction in step a with a proportion of wolfberry, raw rehmannia, raspberry, golden cherry, allium seeds, Morinda officinalis, and toosendan fruit, add 7-12 times the amount of water and boil for 1-3 times, each time for 1-3 hours, filter, combine the filtrate, mix with the alcohol extract obtained in step a, and concentrate under reduced pressure to a relative density of 1.25-1.30 measured at 60° C. to obtain an extract; c. Weigh ginseng, pilose antler, seahorse, Cistanche deserticola, and Cyathula officinalis in proportion, grind them into fine powder and mix them evenly with the extract obtained in step b, dry at 60-70° C., grind, sieve, and fill capsules.
8. The use according to claim 1, It is characterized in that The functions of the erythrocytes are erythrocyte MDA, ROS, Ca 2+ The level of increase.
9. The use according to claim 1, It is characterized in that The function of the red blood cells is red blood cell Na + -K + -Decrease in ATPase activity.
10. The use according to claim 1, It is characterized in that The function of the erythrocytes is a decrease in the level of erythrocyte 2,3-DPG.
11. The use according to claim 1, It is characterized in that The function of the red blood cells is a reduction in the total amount of red blood cell membrane proteins.
12. The use according to claim 1, It is characterized in that The function of the red blood cells is the reduction of the levels of the red blood cell membrane Band3 protein and CD47 protein.
13. The use according to claim 1, It is characterized in that The erythrocyte function is a decrease in the Hb expression level in erythrocytes and / or a decrease in the AchE enzyme activity level in erythrocytes.
14. The use according to claim 1, It is characterized in that The erythrocyte function is an increase in the amount of erythrocyte vesicle release and / or the level of vesicle CD47.
